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 Resumé 
 
Nerve growth factor, NGF, er en neurotrofisk faktor der fremmer vækst, overlevelse og 
differentiering af neuroner. Effekten af NGF induceres via to receptorer, tyrosin kinase receptoren 
TrkA og 75 kDa pan neurotrofin receptoren, p75NTR. 
Aktivering af TrkA initierer intracellulær signaltransduktion via signalvejene Ras/MAP kinase, 
PI3K og PLC-1, hvorved differentiering og overlevelse induceres. NGF’s binding til p75NTR er 
mere kontroversiel og afhænger af det cellulære miljø, idet denne receptor er fundet i stand til 
både at agere pro- og anti-apoptotisk, hvilket blandt andet involverer signalering via NFB, JNK 
og ceramid signalvejene. 
NGF har potentielle fordelagtige effekter i neurodegenerative sygdomme, men administrering og 
transport til hjernen af proteinet er problematisk. På dette grundlag har vi udviklet NGF-
deriverede små peptidsekevenser, der efterligner effekten af NGF proteinet. 
I dette studie blev seks forskellige NGF-deriverede peptider testet på cerebellare granula neuroner 
(CGN) for at undersøge peptidernes neuritogene og neuroprotektive effekter. Tre af disse peptider 
udviste signifikante neuritogene dosis-respons afhængige effekter. hNgf_EE peptidet udviste den 
største effekt, sammenlignet med de to andre peptider, hNgf_C2 og hNgf_E, der fremmede 
neuritogenese. 
Peptiderne hNgf_EE, hNgf_N og hNgf_C1 lod til at øge overlevelsen, hvor den anti-apoptotiske 
effekt for hNgf_EE var den mest udtalte. Ydermere blev de seks NGF-deriverede peptiders evne 
til at binde til hver af de tre Trk receptorer, TrkA, TrkB, TrkC og p75NTR, testet i surface plasmon 
resonance (SPR) assay’et. hNgf_C1, hNgf_D og hNgf_N bandt ikke til nogen af de fire 
receptorer, mens hNgf_C2 bandt til alle fire receptorer og peptiderne hNgf_E og hNgf_EE bandt 
til TrkB, TrkC og p75NTR. 
Dette studie viser at små specifikke NGF-deriverede  peptider er agonister af NGF proteinet og 
særlig hNgf_EE efterligner effektivt den NGF-inducerede neuritogenese og celle overlevelse, der 
muligvis medieres gennem TrkB og /eller TrkC receptorerne, såvel som det muligvis involverer 
p75NTR.  
 
 
 
 
 
Abstract 
 
Nerve growth factor (NGF) is a neurotrophin that promotes growth, survival and differentiation of 
neurons. NGF acts via two different receptors, the tyrosine kinase receptor TrkA and the 75 kDa 
pan neurotrophin receptor, p75NTR.  
Through TrkA, NGF mediates survival and differentiation by using the pathways of Ras/MAP 
kinase, PI3K and PLC-1. However, NGF binding to p75NTR is a double-edged sword causing 
both neuronal survival and death, which involves signaling through NFB, JNK and ceramide 
pathways.  
NGF has potentially beneficial effects in neurodegenerative disorders, but many difficulties are 
associated with administration and cerebral delivery of the native protein. Accordingly, we have 
developed low-molecular weight agonists, which mimick the effect of the NGF protein. 
In the present study six different NGF-derived peptides were tested on cultured cerebellar granule 
neurons (CGN) in order to test the neuritogenic effects and the ability of the six peptides to inhibit 
apoptosis. Three of these peptides were found to promote neurite outgrowth significantly in a 
dose-response dependent manner. The hNgf_EE peptide exhibited the most pronounced effect, 
compared to the two other peptides with neuritogenic effect, hNgf_C2 and hNgf_E.  
The peptides hNgf_EE, hNgf_N and hNgf_C1 seemed to increase survival with the anti-apoptotic 
effect of hNgf_EE being most pronounced. Furthermore the ability of the six different NGF-
derived peptides to bind to each of the three Trk receptors, TrkA, TrkB, TrkC and p75NTR was 
tested in the surface plasmon resonance (SPR) assay. The hNgf_C1, hNgf_D and hNgf_N were 
unable to bind to any of the four receptors, while the hNgf_C2 could bind all four receptors, and 
peptides hNgf_E and hNgf_EE could bind to TrkB, TrkC and p75NTR.  
In conclusion, this study shows that specific, small NGF-derived peptides are agonists of the 
native NGF protein, and in particular hNgf_EE mimicks the NGF-induced neuritogenesis and cell 
survival in a highly effective manner, which likely is mediated through TrkB and/or TrkC 
receptors, as well as it might involve the p75NTR. 
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ara-C Cytosine--D-arabinofuranoside  
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DAG diacylglycerol  
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GAP-43 growth-associated protein 43 
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Grb2 growth factor receptor-bound protein 2  
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IGF-1 Insuline growth factor 1 
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IKKβ IκB kinase-β  
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IP3R IP3 receptor  
IRAK Interleukin 1 receptor-associated kinase 
JNK c-Jun N-terminal kinase  
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MAG myelin-associated glycoprotein  
MAPK Mitogen activated kinase 
MEK MAP and ERK kinase 
NADE p75NTR-associated cell death executor 
      NCAM Neural cell adhesion molecule 
      NFκB Nuclear factor κB 
      NHS N-hydroxysuccinimide 
      NGF Nerve growth factor 
      NT-3 Neurotrophin 3 
      NT-4/5 Neurotrophin 4/5  
      NRIF Neurotrophin receptor interacting factor  
      NRAGE Neurotrophin receptor-interacting  
      MAGE homolog  
Omgp oligodendrocyte myelin glycoprotein                                                      
PACE phosphospecific antibody cell-based ELISA  
      p75NTR 75 kDa pan neurotrophin receptor  
      PBS phosphate buffered saline 
      PC12 pheochromocytoma cell line 12 
      PDK-1 phosphtidylinositide-dependent kinase 1 
      PI3K phosphatidylinositol-3-kinase 
      PIP2 phosphatidylinositol 4,5-biphosphate  
      PKB protein kinase B 
      PKC protein kinase C 
      PLC-1 phospholipase C-1 
      PLL Poly-L-lysine 
      PNS peripheral nervous sytem  
      PTB phosphotyrosine-binding  
      P2Y2 GPCR purinergic receptor 2 
      Rsk ribosomal S6 kinase 
       SEM standard error of mean 
      SH2 src homology 2  
      Shc Src homology 2-containing protein  
      SMAC second mitochondria-derived activator of caspases  
      SOS son of sevenless    
      SPR surface plasmon resonance 
      Trk tyrosine kinase receptor 
      TNFR tumor necrosis factor receptor 
      TRAF tumor necrosis receptor-associated factor   
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1. Introduction 
 
 
Neurotrophins are a family of neurotrophic factors that promote growth, survival, and 
differentiation of neurons in the central and peripheral nervous system (CNS and PNS). The 
neurotrophin family consists of four members which have been identified in mammals: nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and 
neurotrophin 4/5 (NT-4/5) (Allen & Dawbarn 2006). NGF was the first neurotrophin discovered 
in 1953 by Levi-Montalcini and Hamburger. Their discovery came from a mouse sarcoma tumor 
implanted close to the spinal cord of developing chicken in ovo. It was found to secrete a soluble 
factor that induced hypertrophy and fiber outgrowth of sympathetic neurons. Subsequently, in 
vitro studies revealed that this factor was a relatively low molecular weight proteinaceous factor, 
which was later identified as NGF (Cohen & Levi-Montalcini 1956, Cohen 1960). 
NGF acts via cell surface receptors to prevent neuronal death in neuronal development, 
neurodegenerative and psychiatric disorders, ischemia, axotomy, and excitotoxicity (Sofroniew et 
al 2001). The many potentially beneficial effects of NGF signaling raise the possibility of 
therapeutic use of this protein. In spite of this, clinical studies have been disappointing due to the 
many side-effects arising from an aberrant stimulation of various neuronal populations 
(Sofroniew et al 2001). Also, difficulties with sufficient NGF delivery to the CNS limit the 
therapeutic application of NGF.  
Additionally, NGF signaling mechanisms, molecular pathways and the underlying interactions 
with its receptors remain to be elucidated in order to understand and regulate the different NGF 
effects in the CNS. 
These factors limits the therapeutic application of NGF, and common for all are the still limited 
understanding of the signaling mechanisms of the underlying interactions between NGF and its 
receptors and the broad spectrum of effects induced by the signaling pathways. 
An approach to overcoming these problems is the development of low-molecular weight, stable 
molecule agonists or partial agonists that are able to mimic specific effects of the native NGF by 
acting via the NGF receptors. Another advantage of developing small molecule mimetics would 
be the contribution to the elucidation of the NGF-induced signal transduction pathways.  
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2. Theoretical background 
 
2.1 Structure of NGF 
NGF is produced in the CNS during development and throughout adult life. NGF-
producing cells are present in the cortical target regions of basal forebrain cholinergic neurons. 
Most such cells are neurons, though glial cells are occasionally found to express NGF (Pitts & 
Miller 2000). In the hippocampal formation, pyramidal and dentate granule neurons express NGF, 
as do subpopulations of GABAergic interneurons (Lauterborn et al 1993, Pascual et al 1998).  
All the neurotrophins are initially produced as 30-35 kDa precursor proteins. The prepeptides of 
the precursor proteins work as target signals for the translocation of the neurotrophin precursor 
into the lumen of the endoplasmatic reticulum and are thereafter cleaved of. The remaining 
proneurotrophins are cleaved intracellularly by furin, a serine protease, or proconvertases at a 
highly conserved dibasic amino acid cleavage site, releasing the biologically active 12-14 kDa C-
terminal product (Seidah et al 1996, Lessmann et al 2003). 
NGF is expressed in vivo as a preproprotein. The 18 amino acid long N-terminal signal sequence 
targets the preproprotein to the endoplasmatic reticulum. The 103 amino acids comprising the 
propeptide, which does not contain any cysteine residues, is known to promote proper folding in 
vivo and guides oxidative refolding of the mature moiety in vitro (Suter et al 1991). Besides from 
the verified role of the NGF propeptide as a folding facilitator in vivo, it modulates the function of 
NGF by eliciting proapoptotic responses that are likely to be transmitted by both the 75 kDa pan 
neurotrophin receptor (p75NTR) and the sortilin receptor (Lee et al 2001, Nykjaer et al 2004).  
The mature human neurotrophins share significant structural homology, as approximately 50% of 
the amino acids are identical for all the members of the protein family and they therefore share the 
same biochemical characteristics (Lewin & Barde 1996). The structure based alignment of the 
four human neurotrophins, shown in figure 2.1.1, outlines the sequence similarity of their 
sequences.  
 
 
Figure 2.1.1. Structure based sequence alignment of the four human neurotrophins, BDNF, NT-4, NGF and NT-3. 
The stars '*' indicates positions which have a single, fully conserved residue. 
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The core structure of NGF consists of two pairs of intertwined two-strand β-sheets, joined by 
three disulfide bonds. NGF contains a characteristic structural motif, the cysteine knot, formed by 
three disulfide bonds. Two of them, together with the protein backbone that connects the 
cysteines, form a closed ring, which is penetrated by the third disulfide bridge, see figure 2.1.2 
(McDonald et al 1991). 
NGF forms a symmetrical homodimer generated by hydrophobic forces, where two central -
sheets (AB and CD, figure 2.1.2) of the two monomers pack against each other and residues from 
these four  strands are responsible for the majority of interactions that stabilize the dimer. The 
cysteine knot motif, the N- and C-termini, and the loop L3 connecting strands B and C, from each 
monomer, form one end of the dimer. The other end of the dimer is comprised of three hairpin 
loops, L1, L2, and L4, as well as four short -strands arranged in two antiparallel -sheets, see 
figure 2.1.2 (McDonald et al 1991, Wiesmann & de Vos 2001). The Loop L3 is the most different 
among the four neurotrophin structures and is in the NGF protein found to be a reverse turn. The 
N- and C-termini are highly variable in both sequence and structure among the neurotrophins and 
the N-terminus assumes a helical structure upon binding to a tyrosine receptor kinase (Trk) (Butte 
2001). 
 
 
 
Figure 2.1.2. The NGF protein, a) a backbone presentation of the NGF dimer and b) a presentation of the NGF 
monomer (Modified from Allen & Dawbarn 2006, Wiesmann & de Vos, 2001). 
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2.2 Receptors 
Neurons respond to NGF via two cell surface receptors and one of them is the 
transmembrane p75NTR. All neurotrophins bind to a common family of tyrosine kinase cell 
surface receptors with certain specifications. NGF mainly binds to TrkA, BDNF and NT-4/5 to 
TrkB and NT-3 mainly binds to TrkC, but can also bind to TrkA and TrkB (Sofroniew et al 
2001). p75NTR has approximately the same affinity (equilibrium dissociation constant KD = 10-9 
M) for the mature forms of NGF, BDNF, NT3, and NT4/5. Likewise, Trk receptors bind their 
ligands with comparable affinities (KD =  10-9 - 10-10 M; (Bibel et al 1999). 
 
2.2.1 Trk receptors  
The Trk receptors were intially described in human colon carcinoma but are also widely 
expressed in neural tissue, including: the cortex, hippocampus, diencephalon, cerebellum, and in 
neurons of the PNS (Rabizadeh & Bredesen 2003). 
 
The cellular responses regulated by neurotrophin-mediated activation of Trk receptors include 
proliferation and survival, axonal and dendritic growth, assembly and remodeling of the 
cytoskeleton, membrane trafficking and fusion, synapse formation, function and plasticity (Huang 
& Reichardt 2003). Trk receptors share several structural features. They are glycoproteins 
possessing an extracellular ligand-binding domain, which conveys ligand-specificity, a 
hydrophobic transmembrane domain and a cytoplasmic tyrosine kinase domain. Ligand-binding 
to a Trk receptor induces receptor dimerization with conformational changes that result in 
intramolecular phosphorylation of tyrosine residues at multiple sites (Adjei & Hidalgo 2005). 
 
Extracellularly, Trk receptors contain an array of three leucine-rich 24-residue (LRR1-3) motifs 
which was found to be flanked by two cysteine clusters (C1 and C2), followed by two 
immunoglobulin-like domains. In TrkA the second immunoglobulin-like domain, also known as 
domain 5 (d5) has been found to be the major ligand-binding interface. Figure 2.2.1.1 depicts the 
TrkA structure (Wiesmann et al 1999, Robertson et al 2001). 
 
TrkA-d5 folds into an Ig-like domain that consists of a -sandwich formed by two four-stranded 
sheets, A, B, E, D and C’, C, F, G, respectively (Wiesmann et al 1999). The Ig domains are 
followed by a single transmembrane domain and a cytoplasmic domain that contains a tyrosine 
kinase domain and several tyrosine-containing motifs. Phosphorylation of the cytoplasmic 
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tyrosines in Trk receptors regulates tyrosine kinase activity and provides phosphorylation-
dependent recruitment sites for adaptor molecules and enzymes that mediate initiation of 
intracellular signaling cascades (Huang & Reichardt 2003). 
 
Figure 2.2.1.1. Schematic presentation of the TrkA receptor. The three leucine-rich motifs (LRR1-3) are flanked by 
two cysteine clusters (C1 and C2) and after these the two Ig domains. The tyrosine kinase domain is located at the 
intracellular domain (Modified from Allen and Dawbarn 2006). 
 
The crystal structure of NGF bound to a single ligand-binding immunoglobulin-domain of TrkA 
revealed a symmetric 2:2 stochiometry of the complex, see figure 2.2.1.2, establishing 
neurotrophin-induced dimerization as the Trk activation mechanism (Wiesmann et al 1999). Trk 
receptors and neurotrophins interact mainly via hydrophobic and aromatic side-chains (Butte 
2001). NGF engages the TrkA-d5 through two distinct patches. The first patch involves the four 
β-sheets that form the ‘waist’ of the NGF molecule together with the first loop; it includes NGF 
domains that show considerable homology with the other neurotrophins. It is likely that NGF and 
its neurotrophin family members engage each of their Trk receptors through this patch. The 
second patch is formed by the N-terminus of NGF, which in the NGF-TrkA structure is well 
defined. The lack of homology of the NGF N-terminus with other neurotrophins suggests that the 
second patch serves to specify NGF binding to TrkA (Wiesmann et al 1999).  
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Figure 2.2.1.2. A NGF dimer in complex with the d5 domains of two TrkA receptors (Modified from He and Garcia 
2004).  
 
2.3 Signaling pathways mediated by TrkA   
Ligand binding to the Trk receptor causes dimerization, and autophosphorylation of 
tyrosine residues in the extracellular domain, followed by the use of a complex set of intracellular 
signaling cascades. The activation results in phosphorylation of several conserved tyrosines 
present in the cytoplasmic domains of each receptor. Three of these (Y670, Y674 and Y675 in 
human TrkA) are in the activation loop of the kinase domain. Phosphorylation of additional 
tyrosines creates docking sites for proteins containing phosphotyrosine-binding (PTB) or src 
homology 2 (SH2) domains (Cunningham & Greene 1998, Huang & Reichardt 2003). 
Intracellular signaling cascades activated by Trk receptors include the Ras-mitogen activated 
protein kinase (MAPK) cascade pathway, the phosphatidylinositol-3-kinase (PI3K)/Akt kinase 
pathway, as well as phospholipase C-1 (PLC-1; (Kaplan & Miller 2000, Huang & Reichardt 
2001).  
Y490 and Y785 are the major phosphorylated tyrosine residues that are not in the kinase 
activation domain. Y490 interacts with Src homology 2-containing protein (Shc), fibroblast 
growth factor receptor substrate 2 (Frs2), and other adaptor proteins, which provide mechanisms 
for activation of Ras and PI3-kinase. Y785 recruits PLC-γ1 (Obermeier et al 1993, Huang & 
Reichardt 2003).  
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2.3.1 The Ras-MAPK pathway 
Activation of the Ras-MAPK signaling cascade is essential for neurotrophin-promoted 
differentiation of neurons (Huang & Reichardt 2003). Furthermore this signaling mechanism is 
involved in formation of synaptic plasticity, and mediation of long-term potentiation and survival 
(Kaplan & Miller 2000). Several pathways from Trk receptors lead to activation of Ras, most of 
these appear to involve phosphorylation at Y490. Phosphorylated Y490 provides a recruitment 
site for binding of the PTB domain of Shc. After its own phosphorylation, Shc recruits the adaptor 
protein growth factor receptor-bound protein 2 (Grb2), complexed with son of sevenless (SOS), 
which functions as an exchange factor for Ras (Nimnual et al 1998). 
Ras activates Raf, a serine/threonine kinase, and Raf activates MAPK kinase, also called MEK, 
which in turn activates MAPK or extracellular regulated kinase (ERK). MAPK activation results 
in phosphorylation and activation of ribosomal S6 kinase (Rsk) and transcription factors such as 
c-jun, c-myc and c-fos, resulting in the switching on of a number of genes associated with 
proliferation (Adjei & Hidalgo 2005).  
In contrast to the transient activation of MAPK signaling promoted through Shc, Grb2/SOS, and 
Ras, prolonged Erk activation depends on a distinct signaling pathway, Trk signaling appears to 
initiate activation of this pathway by recruitment of Frs2 to phosphorylated Y490. Phosphorylated 
Frs2 provides binding sites for numerous additional signaling proteins, including the adaptors 
Grb2 and Crk, the tyrosine kinase c-Src and the tyrosine phosphatase Shp2. Trk signaling 
increases the association of Crk with Frs2, and this association can also initiate the Erk cascade 
(Kao et al 2001, Huang & Reichardt 2003).  
These events in the MAPK pathway result in the phosphorylation of cyclic AMP-response 
element binding (CREB) transcription factor. CREB regulates genes that are essential for normal 
differentiation and prolonged survival of neurons in vitro and in vivo, and has effects on the cell 
cycle, neurite outgrowth, and synaptic plasticity (Chao 2003). 
  
2.3.2 The PI3K pathway 
Production of P3-phosphorylated phosphoinositides promotes survival of many 
populations of neurons. Phosphatidylinositides are generated by PI3-kinase and activate 
phosphtidylinositide-dependent kinase 1 (PDK-1). Together with these 3-phosphoinositides, 
PDK-1 activates the protein kinase Akt (also known as PKB; (Huang & Reichardt 2003).  
Substrates of Akt include proteins that regulate cell survival in many cell systems and among 
those is the Bad protein. The phosphorylation of Bad promotes cell survival by inducing an 
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interaction between Bad and the scaffolding protein 14-3-3 (Sofroniew et al 2001) which prevents 
it from binding the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-XL.  
The inhibitory binding partner for the Nuclear factor κB (NFκB), IκB, is another substrate of Akt. 
Akt-mediated phosphorylation of IκB promotes its degradation, which results in liberation of 
NFκB. NFκB-promoted gene transcription has been shown to promote neuronal survival (Foehr 
et al 2000, Huang & Reichardt 2003).  
It has been found that PI3-kinase-mediated signaling does not simply promote cell survival, the 3-
phosphoinositides generated by PI3 kinase recruits many signaling proteins to the membrane, 
these include regulators of the Cdc-42-Rac-Rho family of G-proteins that are activated through 
ligand engagement of Trk receptors and control the behavior of the F-actin cytoskeleton. This 
means that the localized Trk-promoted activation of Ras and PI3-kinase accounts for the ability of 
neurotrophin gradients to steer growth cones (Huang & Reichardt 2003, Yuan et al 2003). 
 
2.3.3 The PLC-1 pathway 
The signal transduction pathway for a wide variety of hormone-dependent responses 
include the transient mobilization of intracellular-free Ca2+ and the activation of the protein kinase 
C (PKC) isozymes. The activation of these two second messenger pathways is controlled by the 
phosphorylation of Y785 on TrkA, which binds and activates the PLC-γ1 so that the PLC-γ1-
dependent hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) can take place. This 
hydrolysis releases the second messenger molecules inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG; (Huang & Reichardt 2003). 
IP3 triggers release of Ca2+ from internal Ca2+-stores into the cytosol through the IP3 receptor 
(IP3R). Although the molecular events downstream of Ca2+-fluxes are not well understood in 
nerve growth, calmodulin (CaM; (VanBerkum & Goodman 1995), an intracellular Ca2+-receptor 
protein, calcineurin which is a CaM-dependent protein phosphatase and the Ca2+-CaM-dependent 
protein kinase II are all involved in regulation of nerve growth. 
DAG stimulates DAG-regulated PKC isoforms, which subsequently can activate the Erk cascade 
via Raf (Huang & Reichardt 2003, Arevalo & Wu 2006). 
An overview of the Ras-MAPK, the PI3K and the PLC-γ1 pathway is shown in figure 2.3.3.1. 
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2.3.4 Signaling endosomes 
Although neurotrophins have local effects on signal transduction at axon terminals which 
affect growth cone motility and exocytosis, it is well established that signal transduction in the 
cell soma and nucleus is essential to promote neuronal survival and differentiation. Internalization 
of the NGF-TrkA complex plays an important role in intracellular signaling, particularly in 
neurons, where retrograde transport of the ‘signal’ from distant axon terminals is required to 
trigger signaling pathways in the cell body. This internalization involves endocytosis and the 
formation of signaling endosomes (Sofroniew et al 2001). 
On the cell surface, Trk receptors are enriched in caveoli-like areas of the plasma membrane. 
Ligand engagement stimulates internalization of Trk receptors through clathrin-coated pits and by 
macropinocytosis in cell surface ruffles. After internalization, neurotrophins are localized with 
Trk receptors in endosomes. Retrograde transport of these endosomes provides a mechanism 
through which neurotrophin-mediated signals can be conveyed from axon terminals to the cell 
soma and nucleus (Riccio et al 1999, Huang & Reichardt 2003). 
 
 
 
Figure 2.3.3.1. An overview of the different signaling pathways mediated by the Trk receptors (modified from Huang 
& Reichardt 2003). 
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2.4 p75 NTR  
During development of the CNS, p75NTR is widely expressed in the telencephalon, 
including the neocortex and the hippocampus, in the myencephalon, and in the mesencephalon. In 
the mature CNS, p75NTR can be found in basal forebrain cholinergic neurons, motor neurons, and 
the cerebellar Purkinje neurons (Rabizadeh & Bredesen 2003). 
 
p75NTR is a member of the tumor necrosis factor receptor (TNFR) family and the extracellular 
domain of p75NTR consists of four cysteine-repeat domains (CRD). Both CRD2 and CRD3 have 
been implicated in neurotrophin-binding. p75NTR has a transmembrane and a cytoplasmic domain, 
the latter contains a death domain, see figure 2.4.1 (Huang & Reichardt 2003). The nuclear 
magnetic resonance structure of the intracellular p75NTR region shows a flexible juxtamembrane 
region and a death domain that consists of two perpendicular sets of three helices packed into a 
globular structure (Liepinsh et al 1997). 
Two different regions of p75NTR has been shown to be required for cell death induction, the 
juxtamembrane region named ‘chopper’ and the fourth and fifth α-helices of the six α-helices 
comprising the death domain in p75NTR (Rabizadeh & Bredesen 2003). 
 
Figure 2.4.1. Schematic presentation of p75NTR, showing the four cysteine repeat domains (CRD) and the death 
domain (Modified from Allen & Dawbarn 2006). 
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The crystal structure of NGF in complex with the extracellular domain of p75NTR revealed a 2:1 
NGF/p75NTR stochiometry, in which p75NTR induce conformational changes in NGF that inhibits 
the binding of a second p75NTR to the complex. The overall structure of the NGF/p75NTR complex 
can be described as a roughly parallel configuration, in which the long axis of p75NTR aligns with 
the seam formed by the edge of the NGF dimerization interface, see figure 2.4.2. Since the 
neurotrophins normally exist as biologically active dimers it would be expected that the ligand 
dimer would bind to a dimeric receptor, but in the case of NGF, only one p75 NTR molecule 
contacts the NGF dimer (He & Garcia 2004). 
The complex is held together through two spatially separated binding sites, designated site I and 
site II, see figure 2.4.2. The site I is formed between the wider end of the NGF dimer and the first 
and second CRDs of p75NTR. Site II is formed between the bottom of the NGF dimer and the 
junction between the CRD3 and CRD4 domains of p75NTR (He & Garcia 2004). 
 
Figure 2.4.2. Structure of p75NTR complexed with NGF. a) Backbone presentation of the NGF dimer. p75NTR binds 
along one side of the NGF dimer. NGF monomer A is coloured green and B, blue. p75NTR is purple and the disulfide 
bonds are shown in green. b) Front view of p75NTR binding across the NGF dimerization interface (Modified from He 
& Garcia, 2004). 
 
Both site I and site II have large areas of hydrophobic surface with salt bridges and hydrogen 
bonds providing the binding site for the NGF protein. The overall negative charge of p75NTR is 
important in ligand recognition of the overall basicly charged NGF (He & Garcia 2004). 
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Two binding epitopes for p75NTR have been identified on the surface of NGF. One patch include 
mostly positively charged residues in loops L1 and L4 at the surface proximal to the membrane, 
whereas the second patch contains hydrophilic residues from the highly conserved loop L3 and 
the C terminus. In the complex formed between the NGF dimer and TrkA-d5, only two of these 
residues have minor contacts to TrkA-d5, indicating that the neurotrophins could bind to p75NTR 
and Trk simultaneously (Wiesmann et al 1999, He & Garcia 2004). 
The presence of p75NTR enhances the specificity of TrkA and TrkB for their primary ligands, 
NGF and BDNF, respectively (Brennan et al 1999). This makes the p75NTR able to form higher 
order complexes with several other receptors, these include recently described interactions with 
membrane-associated proteins such as LINGO, the Nogo receptor, and sortilin (Nykjaer et al 
2004, Mi et al 2004). Recent work has also shown that p75NTR interacts with the Nogo receptor as 
a signal-transmitting subunit that mediates inhibitory effects on axonal outgrowth of three myelin-
associated glycoproteins – Nogo, myelin-associated glycoprotein (MAG), and oligodendrocyte 
myelin glycoprotein (Omgp;(Wang et al 2002). 
 
2.5 Signaling pathways mediated by p75NTR 
Neurotrophin binding to p75NTR promotes survival of some cells and apoptosis of other 
cells, while it also affects axonal outgrowth in neurons both in vivo and in vitro. p75NTR exerts 
these diverse actions through a set of signaling pathways, largely distinct from those activated by 
Trk receptors. Prosurvival pathways activated by p75NTR include NFκB and Akt. Ligand binding 
to p75NTR also stimulates several proapoptotic pathways, which include the c-Jun N-terminal 
kinase (JNK) signaling cascade, sphingolipid turnover, and association with several adaptors that 
directly promote cell cycle arrest and apoptosis. p75NTR also activates the small G-proteins Rac 
and Rho that directly affect growth cone motility (Harrington et al 2002). 
 
2.5.1 The NFB pathway 
NGF promotes the association of the adaptor protein tumor necrosis receptor-associated 
factor 6 (TRAF6) with the juxtamembrane region of p75NTR. Interleukin 1 receptor-associated 
kinase (IRAK) is recruited to this complex, leading to formation of a complex of TRAF6 and 
IRAK with atypical protein kinase C-ι (aPKC-ι) and the aPKC-ι-interacting protein, p62. IκB 
kinase-β (IKKβ), a known substrate of aPKC-ι, is recruited to the complex, which results in 
phosphorylation and degradation of IκB and leads to the activation of NFκB (Khursigara et al 
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1999, Khursigara et al 2001). Some of the well known targets for NFB that may mediate its anti-
apoptotic actions include the antioxidant enzyme manganese superoxide dismutase, and the 
calcium binding protein, calbindin D28k (Mattson et al 2000).  
 
2.5.2 The JNK pathway 
Trk receptor activation suppresses the activation of the JNK cascade by p75NTR-mediated 
signaling. In the absence of Trk receptor activation, the activated JNK cascade promotes 
apoptosis through elevation of p53 (Miller & Kaplan 2001). Most studies which have examined 
p75NTR-induced apoptosis suggest that p75NTR induces an intrinsic apoptotic cascade that involves 
the activation of a member of the Rho family of GTPases, Rac1, and JNK, which can induce the 
downstream apoptosis signal c-jun and thereby mediate the release of cytochrome c and the 
second mitochondria-derived activator of caspases (SMAC) from the mitochondria. This leads to 
cleavage and thereby activation of caspase 9, 6, and 3 (Harrington et al 2002). 
Neurotrophin receptor interacting factor (NRIF) is a zinc finger protein, and upon binding of NGF 
to p75NTR, it functions in association with TRAF6 to induce activation of JNK. NRIF induced cell 
death through p75NTR requires p53 and nuclear translocation of NRIF. 
Neurotrophin receptor-interacting MAGE homolog (NRAGE) also interacts with p75NTR to 
mediate neurotrophin-induced cell death through a mechanism that involves cell cycle arrest, JNK 
activation, cytosolic cytochrome c accumulation, and activation of caspases 3, 7, and 9. The NGF-
dependent apoptosis mediated by NRAGE is blocked by the expression of TrkA, which competes 
with NRAGE for binding to p75NTR (Salehi et al 2000). Furthermore, it has been shown that the 
p75NTR-binding protein named p75NTR-associated cell death executor (NADE) which, when bound 
to the 14-3-3ε protein, induced apoptosis through the activation of caspase 3 (Kimura et al 2001). 
2.5.3 The ceramide pathway 
The ceramide pathway promotes apoptosis and mitogenic responses in different cell types 
through control of many signaling pathways, which include Erk, PI3-kinase, and aPKC-ι. For 
example, ceramide binds to Raf and may induce formation of inactive Ras-Raf complexes, 
thereby inhibiting Erk signaling (Muller et al 1998). The ceramide production can then stimulate 
JNK activation (Dobrowsky et al 1994, Dobrowsky et al 1995). Ceramide also inhibits the 
activity of PI3-kinase, either by modifying the association of receptor tyrosine kinases and PI3-
kinase with caveolin in lipid rafts or by directly inhibiting PI3-kinase activity (Huang & Reichardt 
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2003). Figure 2.5.3.1 shows an overview of the p75NTR-mediated pathways, NFB, JNK and the 
ceramide pathway. 
 
Figure 2.5.3.1. An overview of the signaling pathways mediated via binding of NGF to p75NTR (Modified from Huang 
& Reichardt 2003). 
 
2.5.4 Nuclear translocation of p75NTR 
The intracellular domain (ICD) of p75NTR, p75ICD, can be released and translocated to the 
nucleus in response to both NGF and other neurotrophins. Upon binding of NGF to p75NTR, the 
release of p75ICD involves two sequential cleavages of the transmembrane protein. The first 
cleavage occurs in the extracellular part of the protein and is mediated by the metalloproteinase 
α-secretase, while the second cleavage occurs in the intramembrane region and is mediated by a 
-secretase. The final result is the release of the intracellular domain, which traffics to the nucleus 
and acts as a transcriptional regulator. It has been shown that the release of p75ICD does not 
require a previous internalization step and that it can take place directly at the cell surface and 
does thereby represent a novel neurotrophin-mediated signaling pathway (Frade 2005). 
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2.6 Signaling pathways mediated by TrkA/p75 NTR  
The ability of Trk and p75NTR receptors to present different binding sites and affinities to 
particular neurotrophins determines both their responsiveness and specificity. The ratio of 
receptors is important in dictating the numbers of surviving cells, and interactions between 
p75NTR and Trk receptors provide greater discrimination between different neurotrophins (Barker 
& Shooter 1994, Canossa et al 1996, Chao 2003).  
The p75NTR receptor binds physically to the Trk receptors (Bibel et al 1999). It has been reported 
that upon binding of NGF to p75NTR a bend of the entire NGF molecule is induced, making it 
difficult for another p75NTR-molecule to interact with the NGF dimer. The TrkA binding site on 
NGF, composed of the central -sheet, is unaffected by the conformational changes induced by 
p75NTR, since these changes are localized to the distal loops of NGF, see figure 2.4.2 (He & 
Garcia 2004).  
As mentioned earlier, neurotrophins bind their receptors with two different affinities: low-affinity 
(KD = 10-9M) and high-affinity (KD = 10-11M). The binding of the neurotrophins to their receptors 
have generally been considered to be of high affinity. However, in reality the binding of NGF to 
TrkA, and of BDNF to TrkB is of low affinity (KD = 10-9 - 10-10M), but it can be regulated by 
receptor dimerization, structural modifications or association with the p75NTR receptor (Esposito 
et al 2001, Rabizadeh & Bredesen 2003). Figure 2.6.1 shows the binding between TrkA, NGF and 
p75NTR, in the 1:2:1 ratio. 
 
 
Figure 2.6.1. The 1:2:1 TrkA/NGF/p75NTR ratio (Modified from He & Garcia 2004). 
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In most cases, p75NTR functions as a ligand-stimulated apoptotic receptor, inducing the activity of 
the JNK-p53 apoptosis pathway, and of other proteins that regulate cell death such as NRIF. Trk, 
through Ras and PI3K/Akt, can interfere with p75NTR-induced apoptosis by suppressing the JNK-
p53 pathway upstream of JNK, or by inhibiting the activities of cell death proteins. p75NTR, in 
turn, can suppress Trk induced cell survival and growth pathways, possibly through ceramide-
mediated inhibition of Akt and Raf activities (Kaplan & Miller 2000). 
Trk signaling silences p75NTR mediated apoptotic pathways, such as the JNK-p53 pathway, and 
the cross-talk between these two receptors appear to be bidirectional, with p75NTR modulating 
certain Trk signaling pathways, see also figure 2.5.3.1 (Kaplan & Miller 2000). 
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2.7 The NGF mimetics 
In cells there is a high level of proteolytic degradation of proteins and together with the 
difficulties associated with their administration, the general application of proteins as 
therapeutical compounds are limited. It is therefore of great importance to search for small 
mimetic peptides and nonpeptidic compounds that bind to selective receptors and either mimic or 
antagonize neurotrophin activity. The identification of new compounds with neuritogenic and/or 
neuroprotective activities is frequently based on a target molecule and agonists or antagonists can 
be identified based on structural knowledge of the receptor binding site(s).  
Concerning the development of mimetics derived from the NGF protein, it has been suggested 
that without ligand bound, the monomeric p75NTR is proapoptotic and that homodimerization 
induced by neurotrophin binding eliminates this effect (Wang et al 2000). This is consistent with 
studies showing no effects on survival with monomeric p75NTR ligands and monomeric cyclic 
peptides, whereas related bivalent forms in each study promoted cell survival (Longo et al 1997, 
Maliartchouk et al 2000). Since NGF only engages one p75NTR molecule (He & Garcia 2004), it 
means that there is a possibility that small molecules mimicking a single p75NTR-interacting 
domain of NGF might be found capable of competing with NGF binding and/or modifying 
p75NTR-signaling and regulating cell survival. 
As mentioned earlier, two sites of p75NTR are involved in binding to the NGF dimer, site I and site 
II, respectively, both sites have large hydrophobic areas, with salt-bridges and hydrogen bonds 
that provide a binding site for NGF (He & Garcia 2004). Based on this evidence, an eventual 
NGF-derived peptide that carry an overall positive charge and is hydrophobic would potentially 
be interfering with p75NTR and thereby mediating or affecting survival through this receptor. 
The NGF-derived peptides used in this study, were tested on cerebellar granule neurons (CGN) 
from postnatal day 3 rat pups, see section 4.2.2, and in these pups it has been found that CGN 
express TrkB, the specific receptor for BDNF, but not TrkA. This finding is consistent with 
previous findings of trkB, but not trkA mRNA. Furthermore the p75NTR protein has been detected, 
which is also consistent with previous findings of p75NTR mRNA (Courtney et al 1997, 
Numakawa et al 1999).  Thus, if the peptides should have any effect on the cerebellar neurons, 
they would have to mediate eventual anti-apoptotic and neuritogenic effects through the p75NTR 
receptor and/or through the TrkB receptor. 
The TrkA-d5 domain has been shown to be the major ligand-binding domain in the TrkA receptor 
(Wiesmann et al 1999, Robertson et al 2001) and for the TrkB-d5 and the TrkC-d5, it has been 
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shown that domain 5 is sufficient for binding of the respective ligands and regulates the 
specificity of ligand binding (Urfer et al 1995). 
The TrkA-d5, TrkB-d5 and TrkC-d5 share 41 to 44% pairwise sequence identity (Ultsch et al 
1999), see figure 2.7.1. 
 
 
Figure 2.7.1. Sequence alignment of the ligand-binding domain of the Trk receptors. The secondary structural 
elements of TrkA-d5 are shown across the top. Identical residues are shaded light gray, ligand binding determinants 
identified by alanine mutagenesis are shaded red, and residues in contact with NGF are boxed (Modified from Ultsch 
et al 1999). 
 
 
The high structural degree of conservation is reflected in the structural similarity between the 
molecules. The three Trk-d5 domains fold into Ig-like structures consisting of two -sheets, 
ABED and GFCC’and in addition a short helical segment is present in the loop connecting strands 
E and F (Ultsch et al 1999), see figure 2.7.2. 
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Figure 2.7.2. Models of the ligand-binding domains of the three Trk-d5 domains. The -strands are shown in green 
and labelled in TrkA-d5. A helical segment is depicted as a red ribbon and loops are coloured yellow and labelled in 
TrkB-d5 and TrkC-d5 (modified from Ultsch et al 1999). 
 
In the structure between NGF and TrkA, two separate patches on the surface of NGF are in 
contact with TrkA-d5 (Wiesmann et al 1999). One of these patches was suggested to be important 
for complex formation with their ligands of all Trk receptors, and was termed the common patch, 
while the other patch is specific for the interaction between NGF and TrkA, and was thus termed 
the specific patch (Ultsch et al 1999). 
The common patch is formed by residues from the loops at the C-terminal pole of the Ig-like 
domain, and includes the tips of the A’B, C’D and the EF loop as well as the C-terminus of the 
domain. The EF loop and the N terminus of strand F contain the region with the highest sequence 
conservation in the entire extracellular portion of the Trk receptors (Ultsch et al 1999), see figure 
2.7.1. The specific patch on TrkA-d5 involves its ABED sheet in contact with the N terminus of 
NGF (Wiesmann et al 1999), and residues in this region is important for ligand-binding of TrkA-
d5, but not TrkC-d5 (Urfer et al 1998). A comparison of the structures of TrkA-d5, TrkB-d5 and 
TrkC-d5 reveals how TrkA-d5 discriminates between NGF and the other neurotrophins. The key 
feature of this patch, is a hydrophobic pocket formed by residues at the exposed surface of the 
ABED sheet of TrkA-d5. In the complex with NGF, this pocket accommodates the side-chain of 
Ile 6 from the N terminus of NGF. The bottom of this pocket, shown in figure 2.7.3, is formed by 
a disulfide bridge on the exterior of the Trk domain, and the side-chains of Val 294, Met 296, Pro 
302 and Leu 333 form the walls. While the disulfide bridge at the bottom is conserved in the other 
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Trk receptors, the residues forming the wall are not. In TrkB the respective positions are occupied 
by threonine, aspartic acid, proline and histidine residues, giving rise to a hydrophilic pocket 
incapable of binding the hydrophobic N terminus of NGF. Even more dramatic are the changes in 
the structure of TrkC-d5. Here the side-chains of Met 296 and Pro 302 are replaced by arginine 
and glutamic acid, which forms a saltbridge on top of the disulfide bridge and fill the pocket, see 
figure 2.7.3 (Ultsch et al 1999). 
 
 
Figure 2.7.3. Close-up view of the disulfide bridge on the exterior of the ABED sheet. The first is the TrkA-d5, the 
second the TrkB-d5 and the third the TrkC-d5 (Modified from Ultsch et al 1999). 
 
In this study, six different peptides were constructed based on the structure of the NGF protein. 
These peptides were obtained by synthetic production, in which a given amino acid sequence 
within the NGF protein was synthezised. All the NGF-derived peptides were synthesized as 
dendrimers composed of four monomers coupled to a lysine backbone. The peptides were 
synthezised as dendrimers, since it has been shown that multimeric forms of peptide ligands have 
a higher potency for receptor activation than monomeric forms (Ronn et al 1999). In table 2.7.1 
the sequences for the different peptides are shown. 
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Table 2.7.1. The sequences of the six different NGF-derived peptides. 
 
Peptide 
 
Sequence 
Amino acids 
in NGF 
 
hNgf_C1 
 
H-RIDTACV(>K)(>K)(beta-ala)-NH2   
 
103-109 
 
 
hNgf_C2 
 
H-CVLSRKAVRRA(>K)(>K)(beta-ala)-NH2 
 
110-120 
 
   hNgf_D 
 
H-ETKCRDPNPVDSG (>K)(>K)(beta-ala)-NH2 
 
 
   55-67 
 
hNgf_E 
 
H-RGIDSKHWNSY(>K)(>K)(beta-ala)-NH2 
 
 
68-79 
 
   hNgf_EE 
 
 
H-TFVKALTMDGKQAAWR (>K)(>K) 
(beta-Ala)-NH2 
 
 
   84-100 
 
hNgf_N 
 
H-SSHPIFHRGEFS(>K)(>K)(beta-ala)-NH2 
 
 
2-13 
 
In figure 2.7.4 the sequence of the mature human NGF can be seen and the segments in the 
sequence, shaded in different colours outline the peptide sequences. Above the sequence, the 
secondary structure elements of the NGF protein can be seen. 
 
 
Figure 2.7.4. The sequence of the human NGF protein (human NGF protein gi:189203). Purple letters above the text 
are amino acids involved in binding site I in NGF binding to p75NTR and blue is in site II (He & Garcia 2004). The 
coloured parts outline the six different peptides, green is hNgf_N, light blue is hNgf_D, yellow is hNgf_E, red is 
hNgf_EE and blue is hNgf_C2. The green letters under the sequence show the amino acids involved in the specific 
path required for TrkA binding and the red letters, the common patch (Wiesmann et al 1999). Above the sequence the 
secondary structure elements for the NGF protein is shown (Modified from Ultsch et al 1999). 
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The NGF structure showing the location of the NGF-derived peptides, in figure 2.7.6, is the 2.3 Å 
resolution crystal structure of NGF derived from mus musculus, which means that the peptide 
hNgf_EE is not completely consistent with the shown NGF protein, since the peptide sequences 
are derived from the human NGF. An alignment between the human and the mouse NGF 
sequence shows a homology on 94%, as can be seen from figure 2.7.5.  
 
 10 20 30 40  50 
human    SSSHPIFHRG EFSVCDSVSV WVGDKTTATD IKGKEVMVLG EVNINNSVFK  
mouse    ---------G EFSVCDSVSV WVGDKTTATD IKGKEVTVLA EVNINNSVFR  
 60 70 80 90 
human    QYFFETKCRD PNPVDSGCRG IDSKHWNSYC TTTHTFVKAL TMDGKQAAWR 
mouse    QYFFETKCRA SNPVESGCRG IDSKHWNSYC TTTHTFVKAL TTDEKQAAWR 
 100 120 
human    FIRIDTACVC VLSRKAVRRA   
mouse    FIRIDTACVC VLSRKA----   
Figure 2.7.5: Sequence alignment of the human NGF, gi:189203 and mouse NGF, gi:576008. Different amino acids 
are shaded green. 
 
In the crystal structure of the mouse NGF, it was not possible to see the residues 1-10, which is 
the N-terminus and residues 112-118, which constitutes the C-terminus (McDonald et al 1991). 
This means that in figure 2.7.6, only part of the sequence for the two peptides, hNgf_C2 and 
hNgf_N can be seen.  
 
Theoretical background  
 
23 
 
 
Figure 2.7.6.  The location of the six NGF-derived peptides in the mature monomeric NGF protein. The areas shaded 
yellow outline the peptides. For the hNgf_C2 and hNgf_N peptides, only part of the sequence can be seen. 
 
The hNgf_C1 peptide is composed of amino acids from the D strand, which contains the highest 
sequence conservation in all the neurotrophins. The sequence of hNgf_C1 only differs from the 
BDNF and NT-3 in the positively charged Arg 106, where this has been replaced by the 
hydrophilic Ser 106, see figure 2.1.1, section 2.1. Two of the amino acids in hNgf_C1, Arg 103 
and Val 109, are from the common TrkA binding patch. Based on these observations, it seems 
likely that this peptide could bind to another Trk receptor than TrkA, owed to the high sequence 
conservation. 
The hNgf_C2 peptide is composed of the last part of the D strand and the C-terminus of the NGF 
protein. The sequence is less conserved throughout the neurotrophins, only Cys 110 is conserved. 
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The hNgf_C2 peptide contains Lys 111, and Arg 113, 117 and 118, these amino acids contain a 
long flexible side-chain, with a positively charged end. The flexible side-chain makes lysine and 
arginine suitable for binding to molecules with many negative charges on the surface, as for an 
example p75NTR. 
hNgf_D is composed of a part of the B-strand, and it contains a few conserved amino acids, Glu 
55, Thr 56, Cys 58 and Gly 77. The rest of the amino acids in the peptide have a very low 
sequence homology compared to the other neurotrophins. The hNgf_D peptide contains mostly 
hydrophobic amino acids, making it suitable for interaction with TrkA through the hydrophobic 
patch formed by residues at the exposed surface of the ABED sheet of TrkA-d5, see figure 2.7.3. 
The three amino acids Glu 55 and Asp 60 and 65, carry a strong negative charge, making this 
peptide sequence unsuitable for p75NTR binding. 
The hNgf_E peptide is composed of amino acids from the loop L3 and the C-strand. In the 
neurotrophins, the loop L3 is also a highly conserved region, see figure 2.1.1, section 2.1, 
enhancing the possibility that this peptide could bind to perhaps TrkB or TrkC. hNgf_E contains 
the hydrophilic amino acids Ser 73 and 78 and Asn 77, which could be involved in binding via the 
hydrophilic pocket in TrkB, see figure 2.7.3. Furthermore the hNgf_E peptide has an overall 
positive charge, which is necessary for binding to p75NTR. It has moreover been shown that the 
Ngf_E Trp 76 fits in between p75NTR Pro 135 and Leu 137-Pro 138, and that His 75 is involved in 
contact with p75NTR Pro 138 (He & Garcia 2004).  
The hNgf_EE peptide is composed of a part of the C-strand, the entire loop L4 and part of the D-
strand. Generally the amino acids in this peptide are not very well conserved throughout the 
neurotrophins, only six of the 16 amino acids comprising the peptide are conserved. This peptide 
contains Lys 88, Asp 93, Gln 96, Ala 98, Trp 99 and Arg 100, which are all amino acids involved 
in p75NTR binding via site I in NGF. It has been found that the Lys 88 is involved in a saltbridge 
with p75NTR Asp 41 upon binding (He & Garcia 2004). The large number of amino acids involved 
in p75NTR binding in this peptide greatly enhances the probability, that the peptide will mediate its 
effects through this receptor. Furthermore the loop L4 (Asp 93-Gln 96) has been shown to be 
involved in the biological activity of NGF, which could be consistent with the fact that Asp 93 
and Gln 96 has been shown to interact with p75NTR (Ibanez et al 1991). This peptide also contains 
a majority of hydrophobic amino acids. 
The hNgf_N peptide is composed of the N-terminus of the NGF protein. As mentioned before, 
this site includes the specific site for TrkA binding, which enhances the probability that this 
peptide would mediate its effects through the TrkA receptor. Wiesmann et al. (2001) found that 
the most prominent change in NGF upon binding to the TrkA receptor was the conformational 
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changes in the N-terminal residues 2-9 (Wiesmann et al 1999). In this peptide there is nearly no 
sequence conservation between the corresponding sequence in the other neurotrophins. Only two 
amino acids are conserved (Cys 110 and Leu 112), which makes it unlikely to interact through the 
TrkB or TrkC receptor. This peptide also contains amino acid residues important for an eventual 
binding to p75NTR. The Arg 9, Gly 10 and Phe 12 are involved in p75NTR binding via site II and it 
was found that the hNgf_N Phe 12 fits in between the p75NTR Leu 106 and Pro 135 (He & Garcia 
2004).  
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3. Aims 
 
 
Since the therapeutic application of NGF is limited due to its many side effects and 
difficulties with sufficient drug delivery to the CNS, a series of low-molecular weight, stable 
molecule agonists or partial agonists were developed. These agonists are able to mimick specific 
effects of the native NGF by acting via the NGF receptors. Thus the aim of this study is to 
investigate the neuritogenic and anti-apoptotic effects on CGN from three day postnatal rat pups 
of the six different NGF-derived peptides, hNgf_C1, hNgf_C2, hNgf_D, hNgf_E, hNgf_EE and 
hNgf_N. Furthermore the ability of the six NGF-derived peptides to bind to each of the three Trk 
receptors, TrkA, TrkB, TrkC, and the p75NTR was tested in the surface plasmon resonance (SPR) 
assay.
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4. Materials and methods 
 
4.1 Materials 
4.1.1 Peptides 
            The NGF derived peptides, hNgf_C1 (RIDTACV), hNgf_C2 (CVLSRKAVRRA), 
hNgf_D (ETKCRDPNPVDSG), hNgf_E (RGIDSKHWNSY), hNgf_EE 
(TFVKALTMDGKQAAWR) and hNgf_N (SSHPIFHRGEFS), were synthesized as dendrimers 
composed of four monomers coupled to a lysine backbone by Schafer-N (Copenhagen, 
Denmark). The p2d peptide (GRILARGEINFK), also synthesized as a dendrimer, was from Loke 
(Århus, Denmark). 
4.1.2 Animals 
CGN were obtained from postnatal day 3 Wistar rat pups from Charles River (Sulzfeld, 
Germany) or Taconic Europe (Ejby, Denmark). 
4.1.3 Materials used in neurite outgrowth/survival sssay 
Insulin-like growth factor-1 (IGF-1), HEPES, B27, glutamax, glutamine, sodium pyruvate, 
fetal calf serum (FCS), penicillin and streptomycin were purchased from Gibco BRL (Paisley, 
United Kingdom). Poly-L-lysine (PLL), Cytosine--D-arabinofuranoside (ara-C), trypsin, 
soybean trypsin inhibitor, D-glucose and bovine serum albumine (BSA) were from Sigma-Aldrich 
(Copenhagen, Denmark). Polyclonal rabbit anti-rat growth associated protein-43 (GAP-43) 
antibodies were from Chemicon (Temecula, CA, USA), Alexa Flour 488 goat anti-rabbit IgG 
antibodies and Hoechst 33258 were from Molecular Probes (Eugene, OR, USA) and DAKO 
antifade fluorescence mounting medium was from DakoCytomation (Glostrup, Denmark). 
Phosphate buffered saline (PBS) and Krebs buffer were both from the Panum Substrate 
Departement (Copenhagen, Denmark). Glycine, sucrose, calcium chloride, sodium chloride, 
glycerol and formaldehyde were from Merck (Darmstadt, Germany). Potassium chloride was 
from Riedel-de Häen (Seelze, Germany). All cell culture media was from Gibco BRL, unless 
otherwise noted and cell culture plastic-ware, including 8-well permanox Laboratory-Tek 
chamber slides was from Nunc (Roskilde, Denmark). 
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4.1.4 Materials used for Surface Plasmon resonance 
HBS-EP running buffer, ethanolamine-HCl, glycine-HCl, the amine coupling kit and the 
sensor chip CM4 were from BIAcore AB (Uppsala, Sweden). 
The TrkA, TrkB, TrkC receptors and p75NTR were from R&D systems (Oxon, United Kingdom). 
4.2 Methods  
4.2.1 Purification of peptides 
For purification of peptides on a Sephadex column, approximately 10g of Sephadex 
(Amersham BioScource, Uppsala, Sweden) was used. The Sephadex material was placed in 
demineralized water overnight. The following day the column, and accessories to the column, was 
rinsed with 1M NaOH followed by demineralized water. The water from the Sephadex material 
was changed several times and the column was packed with Sephadex and flushed with 
demineralized water again. The peptide was dissolved in 1ml Milli-Q water and added to a loop 
connected to the column and a pump. 20 fractions of 1000 µl were collected. The peptide was 
expected to be in fraction 5-10 and the concentrations of these fractions were measured on a 
spectrophotometer. 
For purification of peptides the Tube-O-DIALYZER for 1kDa Cut-off (Chemicon Int., United 
Kingdom) was used. The tubes contained a filter for filtering impurities from the peptides and this 
were rinsed in Milli-Q water before use. The peptides were soluted in 1ml Milli-Q water and 
transferred to the tubes. The tubes, with the membranes facing downwards, were placed so that 
the membrane was in contact with Milli-Q water in a bottle. Both were placed on a magnetic 
stirrer with gentle stirring of the water. The water was changed once a day and the peptides were 
dialyzed over three days. Afterwards the concentrations were measured. 
4.2.2 Primary cell cultures 
CGN for the primary cell cultures were isolated from postnatal day 3-4 Wistar rat pups 
(see appendix A). Meninges and blood-vessels were removed from the dissected cerebella, which 
were dissected in ice cold modified Krebs solution (see appendix B). The cerebella were chopped 
and trypsinized and the neurons were washed in the presence of DNase 1 and soybean trypsin 
inhibitor, and cellular debris was pelleted by centrifugation. Afterwards the cells were plated on 
8-well permanox Lab-Tek chamber slides in varying media. 
All cell cultures were incubated at 37ºC in a humidified atmosphere containing 5% CO2. All 
animals were handled in accordance with national guidelines for animal welfare. 
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4.2.3 Neurite outgrowth assay 
For neurite outgrowth the CGN were obtained as described in section 4.2.2 and plated in 
uncoated 8-well permanox Lab-Tek chamber slides at a density of 10.000 cells/cm2 in Neurobasal 
medium supplemented with 2% (v/v) B27, 1% (v/v) glutamax, 1U/ml penicillin and 100µg/ml 
streptomycin, 0.4% (w/v) BSA, 2% (v/v) 1M HEPES. The wells were loaded with 200µl medium 
including cells and 100µl peptide, at concentrations of 0.3µg/ml, 1µg/ml, 3µg/ml, 9µg/ml and 
27µg/ml, and for some experiments 81µg/ml. A positive control with 5µg/ml p2d and a negative 
control with no peptides were also included in each experiment. The cell cultures were left to 
differentiate for 24 hours. 
After differentiation the cells were fixed in 4% (v/v) paraformaldehyde in PBS for 20 minutes. 
After washing in PBS supplemented with 1% (w/v) BSA (PBS-BSA) the cells were 
immunostained with primary rabbit antibodies against GAP-43 (1:1000) in PBS, followed by 
washing with PBS and PBS-BSA and thereafter staining with Alexa Fluor 488 secondary goat 
anti rabbit Ig antibodies (1:1000) in PBS-BSA. Images of at least 200 cells for each well in each 
experiment were obtained systematically by computer assisted fluorescence microscopy as 
previously described (Ronn et al 2000). Briefly, a Nikon Diaphot inverted microscope with a 
Nikon Plan 20x objective (Nikon, Tokyo, Japan) coupled to a video camera (Grundig Electronics, 
Nürnberg, Germany) was used for recordings. The software package Prima, developed at the 
Protein Laboratory (Copenhagen, Denmark), was used to make a stereological evaluation of the 
neurite outgrowth (Ronn et al 2000) by counting the number of neuronal cell bodies and the 
number of intersections between neurites and grid lines in an unbiased counting frame. The ratio 
between the number of intersections and the number of cell bodies in an analyzed area was used 
as an estimate of the neuritogenic activity.  
4.2.4 Survival assay 
For survival assays CGN were obtained as described in section 4.2.2 and plated in PLL-
coated 8-well permanox Lab-Tek chamber slides at a density of 100.000 cells/cm2 in Neurobasal-
A medium supplemented with 2% (v/v) B27, 0.5% (v/v) glutamax, 1U/ml penicillin and 
100µg/ml streptomycin, and a final concentration on 40mM KCl. Basal modified eagle (BME) 
containing 5% KCl, was supplemented with 1 U/ml penicillin and 100µg/ml streptomycin, 1% 
(v/v) sodium pyruvate, 1% (v/v) glutamine and 3.5g D-glucose/liter. 300µl medium with cells 
were plated. 20 to 24 hours after plating, araC was added to a final concentration of 10µM, to 
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avoid proliferation of glial cells, after which the cells were left to differentiate for 6-7 days. 
Apoptotic cell death was induced by washing the cells twice in prewarmed BME, the media was 
changed to BME with only 5mM KCl and to investigate neuroprotective effects, 100µl of the 
peptides were added in the same concentrations as for the neurite outgrowth assay and IGF-1 was 
used as a positive control. Two days after induction of apoptosis, the cells were fixed in 4% (v/v) 
paraformaldehyde and stained with Hoechst 33258 (1:1000). Images of 1000-1500 neurons were 
randomly recorded for each well in each experiment using computer-assisted fluorescence 
microscopy as described for the neurite outgrowth assay. Nuclei from dead and live neurons were 
counted using the software package Prima, developed at the Protein laboratory (Copenhagen, 
Denmark), and the fraction of live neurons relative to the total number of neurons was estimated. 
4.2.5 Surface plasmon resonance 
Binding analysis was performed using a BIAlite instrument (Biacore AB, Uppsala, 
Sweden) at 25°C using HBS-EP running buffer, containing 10mM Hepes, pH 7.4, 150mM NaCl, 
3mM EDTA and 0.005% P20. The TrkA, TrkB and TrkC receptors and p75NTR were immobilized 
on a sensor chip, CM4, using an amine-coupling kit as follows: the chip was activated by 20l 
activation solution, N-hydroxysuccinimide, (NHS) and N-ethyl-N’-(3-diethylaminopropyl)-
carbodiimide (EDC), the protein was immobilized using 30l of a mixture of 4l (0.5µg/ml) 
protein in 50µl 10mM sodium acetate buffer (pH 4.0); and the chip was blocked by 35l blocking 
solution (ethanolamine-HCl). The receptor surface was regenerated between ligand injections 
with 15µl 2mM NaCl or 10mM glycine-HCl, pH 2.5. In the present experiments a flow rate of 
5µl/min was used. 
The curve corresponding to the difference between binding to the Trk receptors or the p75NTR 
receptor and a blank chip was used for analysis. Data were analyzed by nonlinear curve fitting 
using the Biaevaluation software, version 4.1 (Biacore AB, Uppsala, Sweden). 
4.2.6 Statistics 
Data are expressed as mean ± SEM. The SEM values indicate standard error of means 
calculated from at least four independent experiments. Statistical significance of differences was 
performed by analysis of variance (ANOVA) for repeated measures using Dunnett’s multiple 
comparison test as post test for the neurite outgrowth assays. The statistical significance of 
difference for the survival assays was performed by the Kruskal-Wallis test followed by Dunn’s 
post test. GraphPad Prism, version 4.03 for windows (GraphPad software, San Diego California, 
USA) was employed for statistical evaluation. 
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5. Results 
 
5.1 Neurite outgrowth 
An important part of neuronal differentiation is the outgrowth of axons and dendrites, 
collectively known as neurites. The primary morphological event that facilitates synaptic 
connections by neurons is characterized by a process that extends from the cell soma and is led by 
a growth cone. The neurite outgrowth assay is thus an assay of neuronal differentiation, and is 
often used to test the neuritogenic potential of a given substance. The neurons are grown at low 
density, in order to prevent the exchange of growth factors and other substances, through which 
they would otherwise be able to affect the neurite outgrowth in neighboring neurons. In essence, 
neurons are grown for a certain period of time in the presence of the molecule of interest, after 
which the outgrowth of the neurites can be quantified. 
The neuritogenic potential of NGF and the six NGF-derived peptides in CGN cultures were 
evaluated by plating primary CGN at low density on permanox chamber slides. The cells were 
left for 24 hours in the presence of medium alone (untreated control), medium supplemented with 
5µg/ml p2d peptide (positive control), and various concentrations of the six different peptides or 
the native NGF protein. Neurons were stained for GAP-43 to visualize neurites and the neurite 
outgrowth was quantified as described in section 4.2.3. The p2d peptide derived from a 
homophilic binding site in the neural cell adhesion molecule (NCAM), has previously been 
shown to induce neurite outgrowth (Pedersen et al 2004) and was used as a positive control. The 
effects of the control media versus the p2d peptide upon neurite outgrowth are shown in figure 
5.1.1a-c. 
 
 
 
 
 
 
Results 
 
32 
 
 
Figure 5.1.1. CGN were plated at low density and were left to differentiate for 24 hours in the presence of a) medium 
alone (untreated control), b) medium supplemented with 5µg/ml p2d peptide (positive control), various 
concentrations of the six different peptides or the native NGF protein. c) presents the graphical difference between 
untreated controls and positive controls. The overall neuritogenic effect of the positive control compared to the 
untreated controls was tested in a paired t-test with *** p<0.001. 
  
 
The NGF protein was tested for its ability to induce neurite outgrowth in primary CGN at two 
different concentrations. Figure 5.1.2 shows that NGF was not able to induce neurite outgrowth 
compared to the untreated control. The maximal stimulation was found to be 103 ± 17.3% at a 
concentration of 100ng/ml. 
 
Figure 5.1.2. Primary CGN were plated at low density and left to differentiate for 24 hours in the 
presence of medium alone (untreated control), medium suplemented with the p2d peptide (positive 
control), or two concentrations of the NGF protein. Approximately 200 cells were counted for each 
condition tested, and the effect of the protein was compared to the untreated control. Results are 
expressed as the percentage of untreated control and presented as ± SEM, n = 5. The overall 
neuritogenic effect of the NGF protein compared to its untreated control was tested in a one-way 
ANOVA for repeated measurements, and no effect was observed.  
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The neuritogenic effects of the six different NGF-derived peptides appear from figure 5.1.3a-f.  
 
Figure 5.1.3. Primary CGN were plated at low density and left to differentiate for 24 hours in the 
presence of medium alone (untreated control), medium suplemented with the p2d peptide (positive 
control), or various concentrations of the NGF-derived peptides. Approximately 200 cells were counted 
for each condition tested, and the effect of the peptides was compared to the untreated control. Results 
are expressed as the percentage of untreated control and presented as ± SEM, n = 5. The overall 
neuritogenic effect of the NGF-derived peptides compared to their untreated controls was tested in a 
one-way ANOVA for repeated measurements. The results were as follows: hNgf_C1 p<0.05, hNgf_C2 
p<0.01, hNgf_D not significant, hNgf_E p<0.0001, hNgf_EE p<0.0001 and hNgf_N p<0.01. The 
results of the following Dunnett's Multiple Comparison Test was * = p<0.05 and ** = p<0.01.  
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The neuritogenic effect of the hNgf_EE was found to be very pronounced, since this peptide 
significantly enhanced neurite outgrowth with up to 1509 ± 229% at a concentration of 9µg/ml 
and 1498 ± 186% at a concentration of 3µg/ml as compared to the untreated control. In figure 
5.1.4 an example of the neuritogenic effect of the hNgf_EE peptide can be seen. 
 
 
Figure 5.1.4. Primary CGN were plated at low density and left to differentiate for 24 hours in the 
presence of a) medium alone (untreated control), b) medium suplemented with the p2d peptide 
(positive control), or c) 9µg/ml hNgf_EE. 
 
 
The effects of the hNgf_C2 and hNgf_E peptides were not as pronounced as the effects of 
hNgf_EE, but still they showed a strong neuritogenic effect. The hNgf_E peptide showed a 
maximal stimulation of 473 ± 91.86% at a concentration of 27µg/ml, compared to the untreated 
control. The maximal stimulation by hNgf_C2 was found to be 396 ± 147% at a concentration of 
9µg/ml compared to the untreated control. The hNgf_C2, hNgf_E and hNgf_EE peptides seem to 
stimulate neurite outgrowth in a dose-response dependent relationship.  
The hNgf_C1 peptide was found not to promote neurite outgrowth very well, it had its maximal 
stimulation at a concentration of 9µg/ml at 150 ± 77%, but was not significantly different from 
the untreated control. 
hNgf_D and hNgf_N did not show any neuritogenic effects, since their maximal stimulation were 
at 68 ± 13% and 75 ± 17% at the concentrations 9µg/ml and 0.3µg/ml, respectively, when 
compared to the untreated control. Thus, CGN cultures treated with the NGF-derived peptides 
hNgf_EE, hNgf_E and hNgf_C2 exhibited a pronounced dose-dependent neuritogenic response. 
For the hNgf_D and hNgf_N peptides, no stimulation of the neurite outgrowth was observed. 
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5.2 Survival  
The potential of the six NGF-derived peptides were also tested for their ability to inhibit 
apoptosis induced by potassium withdrawal in primary CGN cultures. Primary CGN was plated at 
a higher density than in the neurite outgrowth, allowing the individual neurons to be in close 
proximity, and left to differentiate for 7 days in vitro (7DIV) in medium containg 40mM KCl. On 
day 7 apoptosis was induced by changing to a media with a low potassium concentration (5mM 
KCl) and the cells were left for incubation for 48 hours in the presence of  5mM KCl (negative 
control), medium with 40mM KCl or IGF-1 (positive controls) or various concentrations of the 
six different NGF-derived peptides. Subsequently, the cells were stained with Hoechst 33258 to 
visualize nuclear morphology. In figure 5.2.1a it can be seen that the cells grown in the presence 
of 40mM KCl have large and intact nuclei with dispersed chromatin, while the cells cultured in 
the presence of only 5mM KCl, figure 5.2.1b, have fragmented and condensed chromatin, both 
consistent with an apoptotic mechanism of cell death.  
The growth factor, IGF-1, was used as a positive control in order to test if the neurons in the assay 
had the potential to be rescued from apoptosis by the added NGF-derived peptides. This growth 
factor has previously been shown to be able to inhibit apoptosis in primary CGN both in vitro 
(D'Mello et al 1993) and in vivo (Chrysis et al 2001) and as can be seen from figure 5.2.1c IGF-1 
inhibited apoptosis efficiently. 
 
 
 
Figure 5.2.1. a) Cells cultured in the presence of 40mM KCl, the red arrows mark the intact nuclei b) 
cells cultured in the presence of only 5mM KCl, the green arrows mark the fragmented nuclei and c) 
shows the effect of 50ng/ml IGF-1, used as a positive control, to test if the neurons were able to be 
rescued from apoptosis. 
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The ability of five different NGF-derived peptides to inhibit apoptosis appears from figure 5.2.2a-
f and as can be seen, one of the NGF-derived peptides has anti-apoptotic effects on primary CGN. 
 
 
Figure 5.2.2. Primary CGN were plated and left to differentiate for 7DIV in the presence of 40mM 
KCl, after which they were induced to undergo apoptosis by potassium withdrawal. The cells were 
further incubated for 48 hours, supplemented with a) 40mM KCl, 5mM KCl, 50ng/ml IGF-1, or 
various concentrations of b) hNgf_C1, c) hNgf_D, d) hNgf_E, e) hNGF_EE or f) hNgf_N. Every 
experiment was performed in the presence of the 3 controls, shown in a), 1000-1500 cells were counted 
for each condition tested, and the effect of each peptide was compared to its own apoptotic control 
(5mM KCl). Results are expressed as the percentage of apoptotic control and presented as ± SEM, n = 
4-5. The overall anti apoptotic effect of the NGF derived peptides compared to their apoptotic controls 
was tested in a Kruskal-Wallis test and the results were as follows: hNgf_C1 p<0.05, hNgf_D not 
significant, hNgf_E not significant, hNgf_EE p<0.0001, hNgf_N p<0.05. The result of the following 
Dunn’s post test was * = p<0.05 and *** = p<0.0001.   
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hNgf_EE had stronger anti-apoptotic effects on CGN compared to the other NGF-derived 
peptides and exhibited a dose-dependent anti-apoptotic response. The hNgf_EE peptide showed a 
maximal stimulation of 132 ± 7.8% at a concentration of 3µg/ml as compared to the untreated 
control. The effect of this concentration was similar to the one observed when cells were rescued 
from apoptosis by IGF-1 (132.6 ± 3.1%). The effects of hNgf_E, hNgf_N and hNgf_C1 were not 
as pronounced compared to hNgf_EE. The maximal stimulation with hNgf_E was seen at 9µg/ml 
at 115.6 ± 4.5%, and hNgf_N had its maximal stimulation at a concentration of 3µg/ml on 121.5 ± 
6.2%. A maximal stimulation of 127.5 ± 12% as compared to the untreated control was seen at a 
concentration of 9µg/ml for hNgf_C1.  
hNgf_D did not show any anti-apoptotic effects, its maximal stimulation was on 102.00 ± 5.1% at 
a concentration on 27µg/ml. Only two experiments were conducted for the hNgf_C2 peptide, 
which means that any eventual anti-apoptotic effects are not conclusive, but at 3µg/ml, the 
maximal stimulation was 105.50 ± 9.50%, showing no anti-apoptotic effect. In figure 5.2.3 the 
trend in the effect of the hNgf_C2 on primary CGN can be seen. 
 
Figure 5.2.3. Primary CGN were plated and left to differentiate for 7DIV in the presence of 40mM 
KCl, after which they were induced to undergo apoptosis by potassium withdrawal. The cells were 
further incubated for 48 hours, supplemented with a) 40mM KCl, 5mM KCl, 50ng/ml IGF-1, or 
various concentrations of b) hNgf_C2. Both experiments were performed in the presence of the 3 
controls, shown in a), 1000-1500 cells were counted for each condition tested, and the effect of the 
peptide was compared to its own apoptotic control (5mM KCl). Results are expressed as the percentage 
of apoptotic control and presented as ± SEM, n = 2. 
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5.3 Surface plasmon resonance 
The SPR technique is an optical phenomenon which occurs as a result of total internal 
reflection of light at a metal film-liquid surface (O'Shannessy et al 1993). If the incident light is 
monochromatic and plane-polarized and the interface between the media is coated with a thin 
metal film, the evanescent wave will interact with free oscillating electrons or plasmons, in the 
metal film surface. Therefore, when the surface plasmon resonance occurs, energy from the 
incident light is lost to the metal film, resulting in a decrease in the reflected light intensity 
(O'Shannessy et al 1993, Raghavan & Bjorkman 1995). Whenever a plasmon is excited, one 
photon disappears; this produces a dip in the reflected light at a specific angle, the SPR angle. The 
SPR angle, which is dependent on refractive index of the adsorbate, is measured with a sensor 
chip (Pattnaik 2005). A sensor chip consists of a glass substrate onto which a thin gold film is 
deposited. The gold film is covered with a monolayer of a long hydroxyalkyl thiol, which serves 
as a ‘barrier’ to proteins and other ligands from coming into direct contact with the metal surface. 
Covalently coupled to the hydroxyalkyl thiol is a layer of carboxymethyl dextran, in order to 
produce a hydrophilic surface for the immobilization of macromolecules (O'Shannessy et al 
1993). The immobilization of a protein can be performed either by amine-, thiol-, or aldehyde-
coupling (Pattnaik 2005). To study interactions between two molecules, one of the molecules is 
immobilized on the sensor chip and the second molecule is injected over the chip surface.  
In this study the immobilization was performed by amine coupling, where the carboxyl groups on 
the matrix first is transformed into reactive N-hydroxysuccinimide esters by injection of a mixture 
of NHS and EDC. Secondly, the ligand, dissolved in a low-ionic-strength buffer at a pH below the 
isoelectric point of the ligand, is passed over the activated surface. The ligand is concentrated in 
the matrix by electrostatic attraction between the positively charged ligand and the negatively 
charged carboxyl groups in the matrix. During this process the NHS esters react with nucleophilic 
groups of the protein (the -amino group, the -amino group of lysine and the thiol group of 
cysteine). Finally, the remaining reactive esters are transformed into amides by the injection of 
ethanolamine-HCL (Johnsson et al 1991). The overall principle of the immobilization is 
illustrated in figure 5.3.1. 
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Figure 5.3.1. Principle of the immobilization of proteins to the carboxymethyldextran-modified surface  
(Johnsson et al 1991). 
 
Interactions between the two molecules result in mass changes at the chip surface, which translate 
to refractive index changes and changes in the SPR angle. Changes in the SPR angle are 
monitored as resonance units (RU, where 1000 RU corresponds to a 0.10º change in SPR angle, a 
1.0ng/mm2 change in surface mass). The rates of change in the SPR signal can be analyzed to 
yield apparent rate constants for the association and dissociation phases of the reaction. The data 
derived from the BIAcore systems are in the form of sensorgrams, which are plots of RU versus 
time (Raghavan & Bjorkman 1995). 
The ability of the six different NGF-derived peptides to bind to each of the three Trk receptors, 
TrkA, TrkB, TrkC, and p75NTR was tested in the SPR assay. In the SPR experiments, each of the 
four different receptors were immobilized on a sensor chip with two flowcells, one flowcell was 
coupled to the receptor in question and the other, a blank flowcell, was used as reference. Each of 
the six NGF-derived peptides was flushed over the sensor chip surface with a flow rate on 
5µl/min. The binding response was continuously recorded in RU and presented graphically, as 
sensorgrams, as a function of time. The Langmuir binding model, which is the simplest model for 
a 1:1 interaction between analyte and immobilized ligand of the form  A+B  AB, where A is the 
analyte, in this case the peptides and B is the ligand, which in this case is the receptors.  
This simple model was used to determine the equilibrium dissociation constant (KD), calculated 
from the association (ka) and dissociation (kd) rate constants (ka/kd). The fitting results were 
evaluated using BIAevaluation software, and judged by 2, which is a standard statistical 
parameter in SPR of the closeness of the fit. For good fitting to ideal data, 2 is of the same order 
of magnitude as the noise in RU (typically <2). 
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5.3.1 NGF  
Each of the four different receptors was immobilized on sensor chips, with a blank 
flowcell as reference, and the NGF protein in a buffer suspension was flushed over the receptor in 
question. The NGF protein was thus assessed for its ability to bind to each of the four receptors, 
and it was found that it bound to all four receptors, but with different affinities, see table 5.3.1.1. 
In figure 5.3.1.1a-d, the sensorgrams of NGF bound to TrkA, TrkB, TrkC or p75NTR can be seen. 
 
 
 
 
Figure 5.3.1.1. Sensorgrams showing the binding of NGF to a) the TrkA receptor, b) the TrkB receptor, 
c) the TrkC receptor and d) p75NTR. Each of the four different receptors, TrkA, TrkB, TrkC or p75NTR, 
were immobilized on a sensor chip, and NGF protein was injected. For each experiment, four different 
concentrations of NGF were tested. The binding was measured as the difference in RU between 
identical injections onto the flowcells of a sensor chip, to which were coupled either a receptor or 
nothing (blank flowcell). 
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The apparent ka, kd and KD constants are shown in table 5.3.1.1. It was found that the KD for TrkA 
(KD = 4.63(± 0.30)*10-9 M) was higher than the one observed for TrkB (KD = 9.94(± 0.24)*10-9 
M) and TrkC (KD = 3.56(± 0.42)*10-8 M). As can be seen from figure 5.3.1.1a-d, the binding of 
NGF to p75NTR did not reach equilibrium, meaning that no exact value for NGF binding to p75NTR 
could be obtained. Therefore it can only be concluded that NGF is able to bind to the receptor. 
 
Table 5.3.1.1. Association (ka), dissociation (kd) and equilibrium dissociation (KD) constants of NGF 
binding to the immobilized receptors. Results are shown as mean ± SEM, with n = 4. 2 indicates the 
closeness of the fit, usually 2< 2 RU. 
 
Receptor 
 
Apparent ka (M-1 s-1) 
 
 
Apparent kd (s-1) 
 
 
Apparent KD (M) 
 
 

2
 
 
TrkA 
 
(4.04 ± 1.21)*106 
 
(9.30 ± 2.69)*10-3 
 
(4.63 ± 0.30)*10-9 
 
7.43*10-2 
 
TrkB 
 
(1.72 ± 0.26)*106 
 
 
(1.55 ± 0.0012)*10-2 
 
 
(9.94 ± 0.24)*10-9 
 
 
3.79*10-2 
 
TrkC 
 
(7.99 ± 1.42)*105 
 
(2.68 ± 0.0024)*10-2 
 
(3.56 ± 0.42)*10-8 
1.93*10-2 
 
 
In the SPR experiments the ability of the six different NGF-derived peptides to bind to each of the 
immobilized receptors was investigated and, it was found that hNgf_C1, hNgf_D and hNgf_N 
were not able to bind to any of the three Trk receptors or the p75NTR, at any concentration tested. 
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5.3.2 hNgf_C2 
Using the same approach as with the NGF protein, each of the four different receptors, 
TrkA, TrkB, TrkC or p75NTR, was immobilized on sensor chips, with a blank chip as a reference 
and the hNgf_C2 peptide in a buffer suspension was flushed over the receptor in question. In 
figure 5.3.2.1a-d, the sensorgrams of hNgf_C2 bound to TrkA, TrkB, TrkC or p75NTR can be 
seen. 
 
 
Figure 5.3.2.1. Sensorgrams showing the binding of hNgf_C2 to a) the TrkA receptor, b) the TrkB 
receptor, c) the TrkC receptor and d) p75NTR. Each of the four different receptors, TrkA, TrkB, TrkC or 
p75NTR, were immobilized on a sensor chip, and hNgf_C2 was injected. For each experiment, five 
different concentrations of hNgf_C2 were tested. The binding was measured as the difference in RU 
between identical injections onto the flowcells of a sensor chip, to which were coupled either a receptor 
or nothing (blank flowcell). 
 
As can be seen from figure 5.3.2.1a-d, no equilibrium was reached, which means that it can only 
be concluded that hNgf_C2 was able to bind to the Trk receptors and p75NTR, but no exact values 
for the binding affinities could be estimated. 
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5.3.3 hNgf_E 
Various concentrations of the hNgf_E peptide were injected across sensor chip surface 
with each of the three Trk receptors or p75NTR immobilized in one flowcell, with the other serving 
as a reference. The resulting sensorgrams are shown in figure 5.3.3.1. 
 
 
Figure 5.3.3.1. Sensorgrams showing the binding of hNgf_E to a) the TrkB receptor, b) the TrkC 
receptor, and c) p75NTR. Each of the four different receptors, TrkA, TrkB, TrkC or p75NTR, were 
immobilized on a sensor chip, and hNgf_E peptide was injected. For each experiment, four different 
concentrations of hNgf_E were tested. The binding was measured as the difference in RU between 
identical injections onto the flowcells of a sensor chip, to which were coupled either a receptor or 
nothing (blank flowcell). 
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The hNgf_E peptide was able to bind to both the TrkB and TrkC receptor, see figure 5.3.3.1a and 
b, but not TrkA. Furthermore it was found that binding to the TrkB receptor (KD = 2.54(± 
0.54)*10-7 M) was 10-fold higher compared to the TrkC receptor (KD = 1.06(± 2.27)*10-6 M), see 
table 5.3.3.1. It was also found that hNgf_E was able to bind to p75NTR (KD = 2.60(± 1.04)*10-6 
M), with approximately the same affinity as the one found for TrkC. 
 
 
 
Table 5.3.3.1. Association (ka), dissociation (kd) and equilibrium dissociation (KD) constants of hNgf_E 
binding to the immobilized receptors. Results are shown as mean ± SEM, with n = 4. 2 indicates the 
closeness of the fit, usually 2< 2 RU. 
 
Receptor 
 
Apparent ka (M-1 s-1) 
 
 
Apparent kd (s-1) 
 
 
Apparent KD (M) 
 
 

2
 
TrkB (2.21 ± 0.08)*104 (5.65 ± 0.81)*10-3 (2.54  ± 0.54)*10-7 
 
4.07*10-2 
TrkC (7.39 ± 2.15)*103 (6.60 ± 1.18)*10-3 (1.06 ± 2.27)*10-6 2.81*10-2 
p75NTR (1.06 ± 100.41)*105 (1.39 ± 0.0017)*10-2 (2.60 ± 1.04)*10-6 9.81*10-3 
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5.3.4 hNgf_EE 
Injections of the hNgf_EE peptide were performed across sensor chip surface, with 
immobilized receptor, at different concentrations and the resulting sensorgrams are shown in 
figure 5.3.4.1a-c. 
 
 
 
Figure 5.3.4.1. Sensorgrams showing the binding of hNgf_EE to a) the TrkB receptor, b) the TrkC 
receptor, and c) p75NTR. Each of the four different receptors, TrkA, TrkB, TrkC or p75NTR, were 
immobilized on a sensor chip, and hNgf_EE peptide was injected in different concentrations. For each 
experiment, four different concentrations of hNgf_EE were tested. The binding was measured as the 
difference in RU between identical injections onto the flowcells of a sensor chip, to which were 
coupled either a receptor or nothing (blank flowcell). 
 
 
Figure 5.3.4.1a-c shows that hNgf_EE was able to bind to the TrkB and TrkC receptors, but like 
hNgf_E, it was unable to bind to TrkA. In table 5.3.4.1 it can be seen that the hNgf_EE peptide 
also bound to p75NTR (KD = 2.26(± 0.38)*10-7 M) and it was found to bind 10-fold higher to this 
receptor, compared to the hNgf_E peptide, see table 5.3.3.1. The hNgf_EE peptide was also able 
to bind TrkB (KD = 1.03(± 0.16)*10-8 M) 10-fold higher and TrkC (KD = 6.80(± 2.82)*10-8 M) up 
to 100-fold higher, compared to the hNgf_E peptide.  
Results 
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Table 5.3.4.1. Association (ka), dissociation (kd) and equilibrium dissociation (KD) constants of 
hNgf_EE binding to the immobilized receptors. Results are shown as mean ± SEM, with n = 4. 2 
indicates the closeness of the fit, usually 2< 2 RU. 
 
Receptor 
 
Apparent ka (M-1 s-1) 
 
 
Apparent kd (s-1) 
 
 
Apparent KD (M) 
 
 

2
 
TrkB (6.72 ± 0.73)*105 (6.6 ± 0.22)*10-3 (1.03 ± 0.16)*10-8 4.48*10-2 
TrkC (4.02 ± 1.73)*105 (1.49 ± 0.00021)*10-2 (6.80 ± 2.82)*10-8 2.77*10-2 
p75NTR (7.38 ± 1.42)*104 (1.5 ± 0.00053)*10-2 (2.26 ± 0.38)*10-7 1.85*10-2 
 
Based on the SPR experiments, it was found that the NGF protein binds to TrkA, TrkB, TrkC and 
p75NTR. When testing the six NGF-derived peptides it was found that hNgf_C1, hNgf_D and 
hNgf_N were unable to bind to any of the four receptors. The hNgf_C2 peptide, like NGF, was 
able to bind to all four receptors, whereas hNgf_E and hNgf_EE only binds to TrkB, TrkC and 
p75NTR. 
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6. Discussion and perspectives 
 
6.1 Primary CGN cultures  
The use of primary cultures of CGN has been established almost 30 years ago and has 
since then become a popular in vitro model to study almost every aspect of developmental, 
functional and pathological neurobiology (Contestabile 2002). In this study CGN were used for 
all cell cultures, because they are easy to work with. They are relatively robust and high cell 
numbers can be obtained from each animal, compared to other cell types like hippocampal or 
dopaminergic neurons. More than 90% of the neurons in the mammalian cerebellum are granule 
neurons, and constitutes the largest homogenous neuronal population in the mammalian brain 
(Thangnipon et al 1983, Contestabile 2002). Since the purity of the cell cultures obtained from 
CGN is very high, the cultures may be considered as purely neuronal and it is thus easier to see 
the neuronal response when treated with peptides. To work with primary cell cultures compared 
to immortalized cell lines provides a better insight to an in vivo situation, since immortalized 
cultures often adopts characteristics different from the cell type from which they originated. This 
means that the primary cell cultures represent the best mimic of an in vivo situation, in which it 
still is possible to control the external conditions.  
 
6.2 Evaluation of the neurite outgrowth assay 
In the neurite outgrowth assay the neurons were plated at a low density, in order to 
achieve minor interactions between the neurons and thereby avoid the exchange of growth factors 
or other substances secreted by the cells that could possibly influence the outcome. Furthermore it 
would make the interpretation of the results less complex, since the neurites would be clearly 
defined and separated. The advantage of using a setup like the neurite outgrowth assay is that it is 
a very fast and easy way to investigate the effects of peptides on neurite extension. The drawback 
of the method is also its simplicity, since the system far from mimics an in vivo situation and the 
effects of the peptides seen in culture not can be used for comparison with an effect of the 
peptides in an in vivo model, since these effects could be different both qualitatively and 
quantitatively. Thus, it gives only a very crude idea of the potential neuritogenic effects. 
To obtain useful results it is important that the system works properly, and in this study it was 
tested by applying a peptide with a known neuritogenic potential, the p2d peptide, to the culture 
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as a positive control. In this way it could be tested if the cells in the culture were susceptible to the 
treatment and the peptides to be tested could be compared to the one with a known neuritogenic 
potential. 
6.3 Neuritogenic effects of the NGF-derived peptides 
Six different peptides derived from NGF, were tested for their neuritogenic potential and 
for comparison the native NGF protein was tested too. It was found that the hNgf_EE peptide was 
the peptide exhibiting the most pronounced and significant effects, see figure 5.3.1e, section 5.1, 
compared to the two other potent peptides, hNgf_C2 and hNgf_E. For the hNgf_E peptide and the 
hNgf_C2 peptide the effects were comparable, but the effect induced by hNgf_E was more 
significant due to a lower variation in the results, see figure 5.1.3b and d, section 5.1. hNgf_C1 
did not induce any pronounced effect, and finally the hNgf_D and hNgf_N peptides did not show 
any neuritogenic effects at all. Figure 5.3.1a, c and f, section 5.1 shows that they even seemed to 
decrease neurite outgrowth at all concentrations tested, compared to the negative control. Upon 
testing the NGF protein it was found that the protein had no effect. This observation suggests that 
in order to see a neuritogenic effect of NGF, the protein needs the presence of TrkA, which could 
be interpreted as if NGF-induced neurite outgrowth can not be mediated by p75NTR alone. It could 
therefore be speculated if the neuritogenic effects observed for the NGF-derived peptides could be 
mediated by another Trk receptor and not exclusively through p75NTR.  
A study found that the Rho-family GTPase, Cdc-42, produces signals that are essential for the 
neurite outgrowth of PC12 cells and CGN, which means that the NGF-derived peptides could 
mediate the observed neurite outgrowth through this Rho-family GTPase (Ahmed et al 2006). 
Furthermore it has been found that NGF controls the development of dendrites in hippocampal 
neurons by binding to p75NTR, suggesting that the NGF-derived peptides could possibly be able to 
induce part of the neurite outgrowth through this receptor (Salama-Cohen et al 2005). The NGF-
derived peptides shown to have neuritogenic effects could possibly also mediate their effects 
through the TrkB receptor, since it is known to mediate neurite outgrowth in nearly the same way 
as the TrkA receptor, through the Ras-MAPK pathway, which activates CREB and thereby affects 
neurite outgrowth (Chao 2003) and through the PI3K pathway, which recruits regulators of the 
Cdc-42 family to the membrane, where they control the behavior of the F-cytoskeleton and 
thereby the outgrowth of neurites (Huang & Reichardt 2003).  
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6.4 Evaluation of the survival assay 
It is very easy to investigate eventual survival promoting effects of peptides on neurons 
when using the survival assay, since CGN in culture need a constant depolarizing concentration of 
potassium (20-40mM) in order to differentiate and survive in vitro. The requirement for 
depolarizing culture conditions and therefore, for a state of sustained excitation which allows 
substantial levels of free calcium to be present inside the cell, is believed to mimic the in vivo 
condition related to the establishment of excitatory synapses from mossy fibers onto 
differentiating CGN (Thangnipon et al 1983, Contestabile 2002). When the media containing a 
high potassium concentration is replaced by one with a low concentration (5mM), the CGN die 
through apoptosis and it is in this way possible to investigate anti-apoptotic effects of mimetic 
peptides (Thangnipon et al 1983, D'Mello et al 1993). The major drawback of this assay is that it 
does not mimic physiologic conditions, since potassium withdrawal does not take place in vivo 
and furthermore the cells are taken out of their natural complex environment and this way is 
stressed. A method with a more physiologic approach could be the use of excitatory amino acids 
(EAA), for an example glutamate which acts through the NMDA receptor, since it has been 
shown that EAA also exert toxic effects on CGN in primary cultures. It is believed that 
excitotoxicity contributes significantly  to neuronal loss in certain neurological disorders, 
including cerebral ischemia and epilepsy, and by adding EAA to the cultures it would be possible 
to mimic this situation in vitro (Resink et al 1994). The use of this method would provide, as 
mentioned before, a more physiologic and specific model, but in the present study it was 
necessary to apply a more general model in order to study the effects of the peptides in a 
controlled apoptotic model such as the survival assay, which furthermore is suitable for covering 
a broad range of degenerative diseases. 
To ensure that the model was working properly, three different controls were applied, an 
apoptotic control (5mM KCl) ensuring that it was possible to induce apoptosis in the neurons, a 
positive control (40mM KCl) mimicking a ‘normal’ situation and another positive control (IGF-
1), ensuring that it was possible to rescue the cells from apoptosis in this model. As can be seen in 
figure 5.2.2, section 5.2 there is a clear difference between the 40mM positive control and the 
5mM negative control and in cases where the difference between these two controls was not 
pronounced, the experiments were excluded. In both the neurite outgrowth and the survival assay, 
the results were evaluated by morphological criteria’s, in the neurite outgrowth it was the 
extension of neurites and in the survival assay it was the chromatin condensation and nuclear 
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fragmentation of the dead cells. This is a weakness of both assays since the manual counting of 
live versus dead cells in the survival assay and the counting of neurites versus cells in the neurite 
outgrowth assay, in both assays can bias the data.  
 
6.5 Anti-apoptotic effects of the NGF-derived peptides 
The six NGF-derived peptides were tested for their ability to promote survival in cultures 
with apoptosis induced by potassium withdrawal. In this assay it was shown that hNgf_EE 
induced a statistically significant anti-apoptotic effect. The hNgf_C1 peptide showed a tendency 
to be able to rescue cells from apoptosis at a level just beneath that for the positive IGF-1 control, 
see figure 5.2.2b, section 5.2. hNgf_D did not show any anti-apoptotic effects and the effects of 
hNgf_E was not significant. The anti-apoptotic tendency of hNgf_N was found to be less 
pronounced than that observed for hNgf_C1, see figure 5.2.2b, d and f, section 5.2 and as it was 
seen in the neurite outgrowth assay, hNgf_EE exhibited a significant anti-apoptotic effect and 
rescued cells from apoptosis at a level similar to that seen for the positive control (IGF-1) as can 
be seen in figure 5.2.2e, section 5.2. For the hNgf_C2 peptide, only two experiments have been 
conducted so far, but the trend in the effect, figure 5.2.3b, section 5.2, showed that this peptide 
possibly does not promote survival.  
Agents that are able to increase calcium entry into the cell protect from low potassium-induced 
cell death in CGN, where the activation of a calcium/calmodulin-dependent protein kinase is 
likely to be involved in the neuroprotective effect (Contestabile 2002). This shows that a possible 
mechanism for the NGF-derived peptides to induce survival in cells deprived of potassium, could 
be through the activation of this calcium/calmodulin-dependent protein kinase, which is part of 
the PLC-γ1 pathway, mediated through the TrkA or the TrkB receptor (Huang & Reichardt 2003). 
Furthermore it has been found that BDNF is able to induce survival in CGN through the TrkB 
receptor by a calcium-channel independent component of protection and that binding of both 
BDNF and NGF to p75NTR provided protection dependent on calcium-channel activation 
(Courtney et al 1997), which also provide the possibility that the observed protective effect of the 
NGF-derived peptides could be mediated through p75NTR. 
It has been claimed that NGF promote survival by preventing apoptosis in cells explanted at the 
5th postnatal day, through increased Bcl-2 expression, which is involved in the PI3K pathway 
(Muller et al 1997). CGN used in the survival assay were explanted at the 3-4th postnatal day and 
the rescue from apoptosis by the NGF-derived peptides could be related to the observed role of 
NGF for cells explanted at the 5th postnatal day. 
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6.6 Evaluation of surface plasmon resonance for studying receptor/ligand 
interactions 
The development of the SPR biosensor has made kinetic analysis of most biomolecular 
interactions easily accessible and makes it possible to monitor molecular interactions and defining 
the characteristics of proteins in terms of their specificity of interaction with other molecules. The 
use of SPR technique for studying receptor/ligand interaction has several advantages, but also a 
few drawbacks. There are a number of experimental artifacts that can complicate biosensor 
analysis, including random immobilization of the reactant, mass transport, aggregation and non-
specific binding (Myszka 1999). In this study, the receptors were immobilized by amine coupling 
which is a random process that affects the functionality of the ligand as the orientation of the 
ligand can not be defined. In the process of immobilization, the ligand randomly associates with 
the surface which results in multiple orientations and, potentially, multiple affinities for the ligand 
(O'Shannessy et al 1993, Pattnaik 2005). When a defined orientation of a protein molecule is 
required, this could be solved by introducing cysteine residues at specific sites in the protein to 
allow oriented coupling (Raghavan & Bjorkman 1995). To accurately interpret the rate constants 
of binding reactions, it is important to minimize mass transport. These effects occur when the 
binding rate of analyte to the ligand is faster than diffusion of analyte to the surface. The effect of 
mass transport and aggregation can be reduced by minimizing the amount of immobilized ligand 
and by using high flow rates. Furthermore biological macromolecules often show a tendency to 
interact with surfaces and it is thus necessary to check both receptor and ligand for non-specific 
binding before running the experiment (Myszka 1999, Rich & Myszka 2000). 
The Langmuir binding model was chosen since it is very important in evaluating kinetic data to 
accept the simplest model which fits the data within the limits of the experiment. A more complex 
model could fit the data better, but then the question would be if the improvement would be 
biologically or experimentally significant. 
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6.7 Binding of the NGF-derived peptides to Trk and p75NTR 
The SPR results showed that the NGF protein, as expected bound to the TrkA receptor 
with an affinity on KD = 4.63*10-9 M, which is consistent with values seen in a previous study, 
where the binding between NGF and the TrkA-Ig2 was investigated and a KD = 11.8*10-9 M was 
found (Robertson et al 2001). As expected it was also found that the NGF protein was able to bind 
to the p75NTR, but since no equilibrium was reached in the experiments, it was not possible to 
obtain a value for the affinity, and it can therefore only be concluded that it could bind to the 
receptor. It was furthermore found that the NGF protein was able to bind to both the TrkB (KD = 
9.94*10-9M) and the TrkC (KD = 3.56*10-8M) receptor. The observed apparent equilibrium 
dissociation constant for TrkB was higher than the one observed for the interaction between TrkA 
and NGF and the KD for TrkC was close to the one observed for TrkA. The values for TrkB and 
TrkC was expected to be lower than the value for TrkA, since the N terminus of NGF and the 
specificity patch on TrkA increases the specificity of the binding between NGF and TrkA. These 
observations could to some extent be ascribed to the immobilization technique, where other 
binding sites of the TrkB and TrkC receptors could be exposed which possibly could be more 
susceptible for binding to NGF. The observed binding to TrkB and TrkC could be ascribed to the 
fact that all the neurotrophins are able to bind to the Trk receptors and that the high affinity 
observed for each of the receptors to their preferred neurotrophin is mediated through receptor 
dimerization with p75NTR. 
For the peptides it was found that hNgf_C1, hNgf_D and hNgf_N did not bind to any of the 
receptors in the tested concentration ranges. It would have been expected that the hNgf_C1 would 
have been able to bind either TrkB or TrkC, since it had such high sequence conservation among 
the neurotrophins and also since it was observed that this peptide mediated neurite outgrowth to a 
certain extent and also seemed able to inhibit apoptosis. A peptide derived from BDNF, in which 
Ala 107 in hNgf_C1 have been exchanged to Ser 107, have been developed and tested in SPR, 
where it was found that it was able to bind to TrkB, TrkC and p75NTR (unpublished data, Protein 
laboratory). Based on this finding it was expected that hNgf_C1 would be able to bind at least one 
of the above mentioned receptors, but since the sequence is this short and the alanine containing a 
hydrophobic side chain have been exchanged with serine that have a hydrophilic side chain and 
furthermore have an easily removable hydrogen, which enables it to act as a hydrogen donor, the 
exchange of a single amino acid could affect the receptor binding properties of the two peptides 
significantly.  
 53 
 
The hNgf_D peptide was, based on its sequence, and the results from the neurite outgrowth and 
survival assay, not expected to bind any of the receptors, which was consistent with the 
observations. The hNgf_N peptide would have been expected to bind to the TrkA receptor 
because of its sequence being part of the specific patch for TrkA binding, and possibly to the 
p75NTR because of its content of amino acids important for NGF/ p75NTR binding and furthermore 
because it was found that hNgf_N possibly could inhibit apoptosis in the survival assay. A 
method for validating the observed results would be to immobilize the peptides and flush the 
receptors across these. Another explanation that could lead to the conclusion that the hNgf_C1, 
hNgf_D and hNgf_N peptides was not observed to bind to any of the receptors, could be that the 
binding was of such low affinity that the specific binding was to small to observe, compared to 
non-specific binding.  
The hNgf_C2 peptide was shown to bind all Trk receptors and p75NTR, but as shown in the 
NGF/p75NTR binding study, no equilibrium was reached, see figure 5.3.2.1, section 5.3.2, and 
therefore no constants could be obtained. The finding that this peptide was able to bind to all the 
receptors and had a neuritogenic effect, but no trend towards an anti-apoptotic effect, was 
somehow surprising, since it was expected that it would be able to inhibit apoptosis to some 
extent through at least one of the Trk receptors. A reason for this could be that the peptide 
sequence is not part of a site in NGF that is directly involved in the survival promoting response. 
Upon testing hNgf_E and hNgf_EE it was found that they were both able to bind to the TrkB, 
TrkC and p75NTR, but not the TrkA receptor. The finding that both peptides were able to bind to 
TrkB and TrkC, but not TrkA was consistent with the fact that their amino acid sequence does not 
contain any part of the specific patch necessary for TrkA binding. In agreement with the 
expectation, both peptides were able to bind p75NTR, which could be because of the amino acids 
in the peptide sequences involved in NGF/p75NTR binding. It was found that hNgf_EE had higher 
affinity (KD = 2.26*10-7 M) than hNgf_E (KD = 2.6*10-6 M) for p75NTR, which could be because 
hNgf_EE contains more amino acids involved in the binding between p75NTR and the native NGF 
protein. Furthermore it was found that hNgf_EE also was able to bind TrkB and TrkC (KD = 1.03 
and 6.8*10-8 M, respectively) with an affinity higher than the one observed for hNgf_E (KD = 
2.54*10-7 M for TrkB and KD = 1.06*10-6 M for TrkC). These findings could explain the more 
potent neuritogenic and anti-apoptotic effects of the hNgf_EE peptide, compared to the rest of the 
NGF-derived peptides.  
 
 
 
 54 
 
6.8 Effects of the NGF-derived peptides 
As mentioned in section 2.7, there is a possibility that hNgf_C1, because of its high 
sequence conservation, could mediate an effect through another Trk receptor than TrkA. An 
explanation on the limited neuritogenic effect mediated by this peptide could be that it binds only 
part of the activation site and does thereby not mediate a full response. The very short sequence 
could therefore possibly inhibit a full response via TrkB or TrkC. hNgf_C1 did not show any 
significant neuritogenic effects, but did show a trend toward anti-apoptotic effects. This suggests 
the possibility that hNgf_C1 binds to a site in one of the receptors that could be involved in 
promoting survival rather than neurite outgrowth. In the SPR study this peptide was expected to 
bind at least one of the receptors, since it was found to be able to mediate some response in the 
survival assay. Compared to hNgf_C1, the hNgf_C2 peptide sequence contains three arginine and 
a lysine amino acid, which all have long, flexible and positively charged side chains, which could 
make it more suitable for binding to the negative surface in p75NTR. Furthermore the hNgf_C2 
sequence is longer, which gives it a better chance of interacting with more amino acids in a 
receptor and thereby possibly induce stronger effects. hNgf_C2 was shown to significantly 
promote neurite outgrowth, but did not seem to have any effect on promoting survival in the CGN 
cultures. This observation suggests that the peptide could bind to a side in the receptor, primarily 
mediating neuritogenic responses. Taken together with the results from the SPR study, where 
hNgf_C2 was found to be able to bind to all four immobilized receptors, it was surprising to find 
that the peptide did not induce more pronounced effects in the cell culture studies. These findings 
suggest that the peptide sequence is possibly not part of a site in the native NGF protein that is 
directly involved in mediating strong survival or neuritogenic responses. 
The hNgf_D sequence was found to contain very low sequence homology compared to the other 
neurotrophins (see figure 2.1.1, section 2.1). This could be why it was found that it did not bind 
any of the Trk receptors. Furthermore it contains negatively charged amino acids, which would 
make it unlikely that eventual effects would be mediated through p75NTR, and as expected no 
binding to the p75NTR was observed in the SPR study. This is consistent with the observation that 
hNgf_D did not induce any neuritogenic or anti-apoptotic effects on cultured CGN.  
The hNgf_E peptide was found to have a probability of binding and mediating an eventual effect 
through possibly TrkB or TrkC, which was later confirmed by SPR. The theoretical expectation 
was based on the highly conserved loop L3 that is a part of the peptide sequence. Furthermore it 
was found that certain amino acids in the hNgf_E sequence (see section 2.7) is involved in the 
binding between NGF and p75NTR enhancing the probability that this peptide would mediate 
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eventual effects through the p75NTR, and again this was shown to be confirmed by SPR. These 
observations are consistent with the fact that the peptide mediated a pronounced and significant 
effect on neurite outgrowth.  
The hNgf_EE peptide is comprised of loop L4, which is shown to be important for the activity of 
NGF. The importance of this loop was shown in a study that investigated the effects of NGF-
derived peptides based on loop L4. One of the peptides, a dimeric loop L4 peptidomimetic, was 
able to promote both survival and neurite outgrowth in dorsal root ganglion neurons (DRG; (Xie 
et al 2000). Another study supporting this observation showed that treatment of PC12 cells 
expressing lower levels of TrkA and high levels of p75NTR (TrkA+ p75NTR2+) with cyclic peptides 
derived from loop L4 (residue 92-97) in NGF promoted survival. Compared to this they found 
that B104 cells that do not express TrkA (TrkA- p75NTR2+) did not protect against apoptosis, 
which confirmed that these peptides required the expression of TrkA (Beglova et al 2000). These 
results suggest that also the parts of the hNgf_EE peptide comprised of the C and D strands are 
important for the function of this peptide. Furthermore hNgf_EE contains amino acids which are 
involved in the binding between NGF and p75NTR and through SPR it was confirmed that 
hNgf_EE was able to bind p75NTR. hNgf_EE was also able to bind to TrkB and TrkC, although 
this was not expected because of the low sequence homology between this and the corresponding 
sequence in the other neurotrophins (see figure 2.1.1, section 2.1).  
The hNgf_N peptide is composed of the N-terminus of the NGF protein. This part of the protein 
is meant to be particularly important for TrkA binding and there is nearly no sequence 
conservation between this sequence and those in the other neurotrophins. A computational study 
investigated residues 4-13 of this peptide and found, through a calculation of surface contacts, 
that it could provide high affinity to the TrkA-d5, since all the residues formed interactions with 
the receptor, except Gly 8 and Gly 10, which instead provided conformational flexibility to the 
peptide and allowed it to form an additional interaction with the receptor (Berrera et al 2006). It 
was found that the hNgf_N peptide did not show any neuritogenic effect when tested on cultured 
CGN, but there was a trend toward anti-apoptotic effects, which suggests that the peptide could 
possibly mediate some effects through p75NTR. In the NGF protein there could be certain domains 
that mainly contributes to the anti-apoptotic effect or to the neuritogenic effect. This would 
explain why some of the peptides have been observed to primarily promote neurite outgrowth or 
survival. Since hNgf_N constitutes a very important part of the NGF protein for mediating 
responses through the TrkA receptor, it would be interesting to test this peptide in cell cultures 
known to contain the TrkA receptor, as an example in hippocampal cultures.  
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Even though a given peptide is expected to bind to a given site in a receptor due to the 
composition of amino acids in the peptide sequence, there is a possibility that it binds and 
mediates its effects through an unknown binding site in the receptor or through a binding site with 
lower affinity. In this study the NGF-derived peptides were synthesized as dendrimeric peptides 
and the advantage of using dendrimeric instead of monomeric peptides is that in vivo the Trk 
receptors and the p75NTR are activated by neurotrophin dimers. This suggests that upon testing 
mimetic peptides they would at least have to be dimeric in order to increase the possibility that 
they could induce any receptor activation compared to monomeric peptides that would only by 
chance be able to activate a Trk receptor or p75NTR. The advantage of using dendrimeric peptides 
is thus that they greatly enhance the probability of an interaction between the peptide and the 
receptor and thereby the following activation of the signal transduction pathway.  
A general comparison of proteins versus peptides shows that a protein has a much more complex 
three-dimensional structure than a peptide and in this structure, regions can be found that 
comprises the specificity of ligand/receptor interactions and receptor-activation upon ligand-
binding. The binding sites in the protein often includes amino acid residues that are far from each 
other in the primary sequence and brought close together in the secondary and tertiary structure, 
which shows that the three-dimensional structure of the protein keeps the binding sites in the right 
conformation. But the three dimensional structure of the protein can also partially inhibit binding 
of the protein to the binding site in a receptor through sterical hindrance. In contrast to this 
peptides do not exhibit such sterical hindrance, and could thereby be able to bind better to the 
binding site in the receptor.  
All the NGF-derived peptides only comprise small parts of the complete NGF sequence, which 
means that they can only occupy part of a binding site in the receptor. Therefore peptides with 
longer sequences would occupy more amino acids in the receptor binding site and thus be able to 
induce more specific binding and possibly stronger responses. The shorter the sequence of a 
peptide is, the less specific it would also be, which thereby increase the possibility that this 
peptide could be able to bind to another receptor on the neurons. For all the peptides, which are as 
mentioned before only parts of the NGF sequence and therefore are less specific than the protein, 
there is the possibility that they could interact with yet undiscovered receptors interacting with the 
known receptors or the peptides. Recent evidence has shown that receptor cross-talk is an 
important mechanism for regulation of neurotrophin signaling and it has been found that the 
presence of the receptor c-Ret is essential to observe full trophic responses in sympathetic 
neurons to NGF in vivo. The receptor cross-talk between the Trk receptors and other membrane 
receptors has been found to also include, other than p75NTR, G-protein coupled receptors (GPCRs) 
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and vanilloid receptors (Huang & Reichardt 2003). One of these receptors is the GPCR purinergic 
receptor 2 (P2Y2) that has been shown to interact with the TrkA receptor upon activation with 
NGF and extracellular nucleotides. This convergence point of NGF/TrkA with ATP/P2Y2 leads to 
increased ERK1/2 activation by phosphorylated TrkA, resulting in increased neurite formation in 
both DRG neurons and PC12 cells (Arthur et al 2005). These many receptors involved in cross-
talking makes it difficult to completely ascribe the effects of the NGF-derived peptides to just one 
or two receptors based only on the knowledge of their sequences. An approach to solve this 
problem could be by the immobilization of the receptors shown to be involved in cross-talk and if 
binding to the peptide is observed, this could be followed by co-immobilization of the cross-talk 
receptor with a Trk receptor that the peptide has already been shown to bind to. Another approach 
to distinguish between the possibilities that the observed peptide activity was Trk kinase- and/or 
p75NTR-dependent would be through the addition of Trk kinase inhibitors or p75NTR-blocking 
antibodies in cell culture assays. For the peptides shown to induce neurite outgrowth it would also 
be to identify the amino acids being important for mediating the neuritogenic effects. This could 
be performed by adding truncated forms of the peptide, in the most neurite outgrowth promoting 
concentration known, to CGN cultures or by testing the truncated peptides in SPR.  
Furthermore it will be necessary to test the pathways involved in signal transduction induced by 
the potent peptides, which could be done by the very simple phosphospecific antibody cell-based 
ELISA (PACE) assay in which peptides are added to cultures of CGN after 72 hours of 
incubation and then incubated long enough for the peptides to mediate an effect, after which the 
cells are fixed and immunostained against the phosphorylated pathway intermediates. Finally it 
would be obvious to test the most effective peptide, namely hNgf_EE in a neurodegenerative in 
vivo model. 
 
 
 
 
 
 
 
 
 
 
 58 
 
7. References 
 
 
Literature Cited 
 
 1.  Adjei AA, Hidalgo M. 2005. Intracellular signal transduction pathway proteins 
as targets for cancer therapy. J. Clin. Oncol. 23(23):5386-403 
 2.  Ahmed I, Calle Y, Iwashita S, Nur-E-Kamal. 2006. Role of Cdc42 in neurite 
outgrowth of PC12 cells and cerebellar granule neurons. Mol. Cell 
Biochem. 281(1-2):17-25 
 3.  Allen SJ, Dawbarn D. 2006. Clinical relevance of the neurotrophins and their 
receptors. Clin. Sci. (Lond) 110(2):175-91 
 4.  Arevalo JC, Wu SH. 2006. Neurotrophin signaling: many exciting surprises! 
Cell Mol. Life Sci. 
 5.  Arthur DB, Akassoglou K, Insel PA. 2005. P2Y2 receptor activates nerve 
growth factor/TrkA signaling to enhance neuronal differentiation. Proc. 
Natl. Acad. Sci. U. S. A 102(52):19138-43 
 6.  Barker PA, Shooter EM. 1994. Disruption of NGF binding to the low affinity 
neurotrophin receptor p75LNTR reduces NGF binding to TrkA on PC12 
cells. Neuron 13(1):203-15 
 7.  Beglova N, Maliartchouk S, Ekiel I, Zaccaro MC, Saragovi HU, Gehring K. 
2000. Design and solution structure of functional peptide mimetics of 
nerve growth factor. J. Med. Chem. 43(19):3530-40 
 8.  Berrera M, Cattaneo A, Carloni P. 2006. Molecular simulation of the binding of 
nerve growth factor peptide mimics to the receptor tyrosine kinase A. 
Biophys. J. 
 9.  Bibel M, Hoppe E, Barde YA. 1999. Biochemical and functional interactions 
between the neurotrophin receptors trk and p75NTR. EMBO J. 
18(3):616-22 
 59 
 
 10.  Brennan C, Rivas-Plata K, Landis SC. 1999. The p75 neurotrophin receptor 
influences NT-3 responsiveness of sympathetic neurons in vivo. Nat. 
Neurosci. 2(8):699-705 
 11.  Butte MJ. 2001. Neurotrophic factor structures reveal clues to evolution, 
binding, specificity, and receptor activation. Cell Mol. Life Sci. 
58(8):1003-13 
 12.  Canossa M, Twiss JL, Verity AN, Shooter EM. 1996. p75(NGFR) and TrkA 
receptors collaborate to rapidly activate a p75(NGFR)-associated protein 
kinase. EMBO J. 15(13):3369-76 
 13.  Chao MV. 2003. Neurotrophins and their receptors: a convergence point for 
many signalling pathways. Nat. Rev. Neurosci. 4(4):299-309 
 14.  Chrysis D, Calikoglu AS, Ye P, D'Ercole AJ. 2001. Insulin-like growth factor-I 
overexpression attenuates cerebellar apoptosis by altering the expression 
of Bcl family proteins in a developmentally specific manner. J. Neurosci. 
21(5):1481-9 
 15.  Cohen S. 1960. PURIFICATION OF A NERVE-GROWTH PROMOTING 
PROTEIN FROM THE MOUSE SALIVARY GLAND AND ITS 
NEURO-CYTOTOXIC ANTISERUM. Proc. Natl. Acad. Sci. U. S. A 
46(3):302-11 
 16.  Cohen S, Levi-Montalcini R. 1956. A NERVE GROWTH-STIMULATING 
FACTOR ISOLATED FROM SNAKE VENOM. Proc. Natl. Acad. Sci. 
U. S. A 42(9):571-4 
 17.  Contestabile A. 2002. Cerebellar granule cells as a model to study mechanisms 
of neuronal apoptosis or survival in vivo and in vitro. Cerebellum. 
1(1):41-55 
 18.  Courtney MJ, Akerman KE, Coffey ET. 1997. Neurotrophins protect cultured 
cerebellar granule neurons against the early phase of cell death by a two-
component mechanism. J. Neurosci. 17(11):4201-11 
 19.  Cunningham ME, Greene LA. 1998. A function-structure model for NGF-
activated TRK. EMBO J. 17(24):7282-93 
 
 60 
 
 20.  D'Mello SR, Galli C, Ciotti T, Calissano P. 1993. Induction of apoptosis in 
cerebellar granule neurons by low potassium: inhibition of death by 
insulin-like growth factor I and cAMP. Proc. Natl. Acad. Sci. U. S. A 
90(23):10989-93 
 21.  Dobrowsky RT, Jenkins GM, Hannun YA. 1995. Neurotrophins induce 
sphingomyelin hydrolysis. Modulation by co-expression of p75NTR with 
Trk receptors. J. Biol. Chem. 270(38):22135-42 
 22.  Dobrowsky RT, Werner MH, Castellino AM, Chao MV, Hannun YA. 1994. 
Activation of the sphingomyelin cycle through the low-affinity 
neurotrophin receptor. Science 265(5178):1596-9 
 23.  Esposito D, Patel P, Stephens RM, Perez P, Chao MV, Kaplan DR, Hempstead 
BL. 2001. The cytoplasmic and transmembrane domains of the p75 and 
Trk A receptors regulate high affinity binding to nerve growth factor. J. 
Biol. Chem. 276(35):32687-95 
 24.  Foehr ED, Lin X, O'Mahony A, Geleziunas R, Bradshaw RA, Greene WC. 2000. 
NF-kappa B signaling promotes both cell survival and neurite process 
formation in nerve growth factor-stimulated PC12 cells. J. Neurosci. 
20(20):7556-63 
 25.  Frade JM. 2005. Nuclear translocation of the p75 neurotrophin receptor 
cytoplasmic domain in response to neurotrophin binding. J. Neurosci. 
25(6):1407-11 
 26.  Harrington AW, Kim JY, Yoon SO. 2002. Activation of Rac GTPase by p75 is 
necessary for c-jun N-terminal kinase-mediated apoptosis. J. Neurosci. 
22(1):156-66 
 27.  He XL, Garcia KC. 2004. Structure of nerve growth factor complexed with the 
shared neurotrophin receptor p75. Science 304(5672):870-5 
 28.  Huang EJ, Reichardt LF. 2001. Neurotrophins: roles in neuronal development 
and function. Annu. Rev. Neurosci. 24:677-736 
 29.  Huang EJ, Reichardt LF. 2003. Trk receptors: roles in neuronal signal 
transduction. Annu. Rev. Biochem. 72:609-42 
 30.  Ibanez CF, Ebendal T, Persson H. 1991. Chimeric molecules with multiple 
neurotrophic activities reveal structural elements determining the 
specificities of NGF and BDNF. EMBO J. 10(8):2105-10 
 61 
 
 31.  Johnsson B, Lofas S, Lindquist G. 1991. Immobilization of proteins to a 
carboxymethyldextran-modified gold surface for biospecific interaction 
analysis in surface plasmon resonance sensors. Anal. Biochem. 
198(2):268-77 
 32.  Kao S, Jaiswal RK, Kolch W, Landreth GE. 2001. Identification of the 
mechanisms regulating the differential activation of the mapk cascade by 
epidermal growth factor and nerve growth factor in PC12 cells. J. Biol. 
Chem. 276(21):18169-77 
 33.  Kaplan DR, Miller FD. 2000. Neurotrophin signal transduction in the nervous 
system. Curr. Opin. Neurobiol. 10(3):381-91 
 34.  Khursigara G, Bertin J, Yano H, Moffett H, DiStefano PS, Chao MV. 2001. A 
prosurvival function for the p75 receptor death domain mediated via the 
caspase recruitment domain receptor-interacting protein 2. J. Neurosci. 
21(16):5854-63 
 35.  Khursigara G, Orlinick JR, Chao MV. 1999. Association of the p75 neurotrophin 
receptor with TRAF6. J. Biol. Chem. 274(5):2597-600 
 36.  Kimura MT, Irie S, Shoji-Hoshino S, Mukai J, Nadano D, Oshimura M, Sato 
TA. 2001. 14-3-3 is involved in p75 neurotrophin receptor-mediated 
signal transduction. J. Biol. Chem. 276(20):17291-300 
 37.  Lauterborn JC, Tran TM, Isackson PJ, Gall CM. 1993. Nerve growth factor 
mRNA is expressed by GABAergic neurons in rat hippocampus. 
Neuroreport 5(3):273-6 
 38.  Lee R, Kermani P, Teng KK, Hempstead BL. 2001. Regulation of cell survival 
by secreted proneurotrophins. Science 294(5548):1945-8 
 39.  Lessmann V, Gottmann K, Malcangio M. 2003. Neurotrophin secretion: current 
facts and future prospects. Prog. Neurobiol. 69(5):341-74 
 40.  Lewin GR, Barde YA. 1996. Physiology of the neurotrophins. Annu. Rev. 
Neurosci. 19:289-317 
 41.  Liepinsh E, Ilag LL, Otting G, Ibanez CF. 1997. NMR structure of the death 
domain of the p75 neurotrophin receptor. EMBO J. 16(16):4999-5005 
 62 
 
 42.  Longo FM, Manthorpe M, Xie YM, Varon S. 1997. Synthetic NGF peptide 
derivatives prevent neuronal death via a p75 receptor-dependent 
mechanism. J. Neurosci. Res. 48(1):1-17 
 43.  Maliartchouk S, Debeir T, Beglova N, Cuello AC, Gehring K, Saragovi HU. 
2000. Genuine monovalent ligands of TrkA nerve growth factor 
receptors reveal a novel pharmacological mechanism of action. J. Biol. 
Chem. 275(14):9946-56 
 44.  Mattson MP, Culmsee C, Yu Z, Camandola S. 2000. Roles of nuclear factor 
kappaB in neuronal survival and plasticity. J. Neurochem. 74(2):443-56 
 45.  McDonald NQ, Lapatto R, Murray-Rust J, Gunning J, Wlodawer A, Blundell 
TL. 1991. New protein fold revealed by a 2.3-A resolution crystal 
structure of nerve growth factor. Nature 354(6352):411-4 
 46.  Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J, Levesque M, Allaire N, Perrin S, 
Sands B, Crowell T, Cate RL, McCoy JM, Pepinsky RB. 2004. LINGO-1 
is a component of the Nogo-66 receptor/p75 signaling complex. Nat. 
Neurosci. 7(3):221-8 
 47.  Miller FD, Kaplan DR. 2001. Neurotrophin signalling pathways regulating 
neuronal apoptosis. Cell Mol. Life Sci. 58(8):1045-53 
 48.  Muller G, Storz P, Bourteele S, Doppler H, Pfizenmaier K, Mischak H, Philipp 
A, Kaiser C, Kolch W. 1998. Regulation of Raf-1 kinase by TNF via its 
second messenger ceramide and cross-talk with mitogenic signalling. 
EMBO J. 17(3):732-42 
 49.  Muller Y, Tangre K, Clos J. 1997. Autocrine regulation of apoptosis and bcl-2 
expression by nerve growth factor in early differentiating cerebellar 
granule neurons involves low affinity neurotrophin receptor. Neurochem. 
Int. 31(2):177-91 
 50.  Myszka DG. 1999. Improving biosensor analysis. J. Mol. Recognit. 12(5):279-
84 
 51.  Nimnual AS, Yatsula BA, Bar-Sagi D. 1998. Coupling of Ras and Rac 
guanosine triphosphatases through the Ras exchanger Sos. Science 
279(5350):560-3 
 63 
 
 52.  Numakawa T, Takei N, Yamagishi S, Sakai N, Hatanaka H. 1999. Neurotrophin-
elicited short-term glutamate release from cultured cerebellar granule 
neurons. Brain Res. 842(2):431-8 
 53.  Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen C, 
Kliemannel M, Schwarz E, Willnow TE, Hempstead BL, Petersen CM. 
2004. Sortilin is essential for proNGF-induced neuronal cell death. 
Nature 427(6977):843-8 
 54.  O'Shannessy DJ, Brigham-Burke M, Soneson KK, Hensley P, Brooks I. 1993. 
Determination of rate and equilibrium binding constants for 
macromolecular interactions using surface plasmon resonance: use of 
nonlinear least squares analysis methods. Anal. Biochem. 212(2):457-68 
 55.  Obermeier A, Halfter H, Wiesmuller KH, Jung G, Schlessinger J, Ullrich A. 
1993. Tyrosine 785 is a major determinant of Trk--substrate interaction. 
EMBO J. 12(3):933-41 
 56.  Pascual M, Rocamora N, Acsady L, Freund TF, Soriano E. 1998. Expression of 
nerve growth factor and neurotrophin-3 mRNAs in hippocampal 
interneurons: morphological characterization, levels of expression, and 
colocalization of nerve growth factor and neurotrophin-3. J. Comp 
Neurol. 395(1):73-90 
 57.  Pattnaik P. 2005. Surface plasmon resonance: applications in understanding 
receptor-ligand interaction. Appl. Biochem. Biotechnol. 126(2):79-92 
 58.  Pedersen MV, Kohler LB, Ditlevsen DK, Li S, Berezin V, Bock E. 2004. 
Neuritogenic and survival-promoting effects of the P2 peptide derived 
from a homophilic binding site in the neural cell adhesion molecule. J. 
Neurosci. Res. 75(1):55-65 
 59.  Pitts AF, Miller MW. 2000. Expression of nerve growth factor, brain-derived 
neurotrophic factor, and neurotrophin-3 in the somatosensory cortex of 
the mature rat: coexpression with high-affinity neurotrophin receptors. J. 
Comp Neurol. 418(3):241-54 
 60.  Rabizadeh S, Bredesen DE. 2003. Ten years on: mediation of cell death by the 
common neurotrophin receptor p75(NTR). Cytokine Growth Factor Rev. 
14(3-4):225-39 
 64 
 
 61.  Raghavan M, Bjorkman PJ. 1995. BIAcore: a microchip-based system for 
analyzing the formation of macromolecular complexes. Structure. 
3(4):331-3 
 62.  Resink A, Hack N, Boer GJ, Balazs R. 1994. Growth conditions differentially 
modulate the vulnerability of developing cerebellar granule cells to 
excitatory amino acids. Brain Res. 655(1-2):222-32 
 63.  Riccio A, Ahn S, Davenport CM, Blendy JA, Ginty DD. 1999. Mediation by a 
CREB family transcription factor of NGF-dependent survival of 
sympathetic neurons. Science 286(5448):2358-61 
 64.  Rich RL, Myszka DG. 2000. Advances in surface plasmon resonance biosensor 
analysis. Curr. Opin. Biotechnol. 11(1):54-61 
 65.  Robertson AG, Banfield MJ, Allen SJ, Dando JA, Mason GG, Tyler SJ, Bennett 
GS, Brain SD, Clarke AR, Naylor RL, Wilcock GK, Brady RL, Dawbarn 
D. 2001. Identification and structure of the nerve growth factor binding 
site on TrkA. Biochem. Biophys. Res. Commun. 282(1):131-41 
 66.  Ronn LC, Olsen M, Ostergaard S, Kiselyov V, Berezin V, Mortensen MT, 
Lerche MH, Jensen PH, Soroka V, Saffell JL, Doherty P, Poulsen FM, 
Bock E, Holm A. 1999. Identification of a neuritogenic ligand of the 
neural cell adhesion molecule using a combinatorial library of synthetic 
peptides. Nat. Biotechnol. 17(10):1000-5 
 67.  Ronn LC, Ralets I, Hartz BP, Bech M, Berezin A, Berezin V, Moller A, Bock E. 
2000. A simple procedure for quantification of neurite outgrowth based 
on stereological principles. J. Neurosci. Methods 100(1-2):25-32 
 68.  Salama-Cohen P, Arevalo MA, Meier J, Grantyn R, Rodriguez-Tebar A. 2005. 
NGF controls dendrite development in hippocampal neurons by binding 
to p75NTR and modulating the cellular targets of Notch. Mol. Biol. Cell 
16(1):339-47 
 69.  Salehi AH, Roux PP, Kubu CJ, Zeindler C, Bhakar A, Tannis LL, Verdi JM, 
Barker PA. 2000. NRAGE, a novel MAGE protein, interacts with the 
p75 neurotrophin receptor and facilitates nerve growth factor-dependent 
apoptosis. Neuron 27(2):279-88 
 
 65 
 
 70.  Seidah NG, Benjannet S, Pareek S, Savaria D, Hamelin J, Goulet B, Laliberte J, 
Lazure C, Chretien M, Murphy RA. 1996. Cellular processing of the 
nerve growth factor precursor by the mammalian pro-protein 
convertases. Biochem. J. 314 ( Pt 3):951-60 
 71.  Sofroniew MV, Howe CL, Mobley WC. 2001. Nerve growth factor signaling, 
neuroprotection, and neural repair. Annu. Rev. Neurosci. 24:1217-81 
 72.  Suter U, Heymach JV, Jr., Shooter EM. 1991. Two conserved domains in the 
NGF propeptide are necessary and sufficient for the biosynthesis of 
correctly processed and biologically active NGF. EMBO J. 10(9):2395-
400 
 73.  Thangnipon W, Kingsbury A, Webb M, Balazs R. 1983. Observations on rat 
cerebellar cells in vitro: influence of substratum, potassium concentration 
and relationship between neurones and astrocytes. Brain Res. 
313(2):177-89 
 74.  Ultsch MH, Wiesmann C, Simmons LC, Henrich J, Yang M, Reilly D, Bass SH, 
de Vos AM. 1999. Crystal structures of the neurotrophin-binding domain 
of TrkA, TrkB and TrkC. J. Mol. Biol. 290(1):149-59 
 75.  Urfer R, Tsoulfas P, O'Connell L, Hongo JA, Zhao W, Presta LG. 1998. High 
resolution mapping of the binding site of TrkA for nerve growth factor 
and TrkC for neurotrophin-3 on the second immunoglobulin-like domain 
of the Trk receptors. J. Biol. Chem. 273(10):5829-40 
 76.  Urfer R, Tsoulfas P, O'Connell L, Shelton DL, Parada LF, Presta LG. 1995. An 
immunoglobulin-like domain determines the specificity of neurotrophin 
receptors. EMBO J. 14(12):2795-805 
 77.  VanBerkum MF, Goodman CS. 1995. Targeted disruption of Ca(2+)-calmodulin 
signaling in Drosophila growth cones leads to stalls in axon extension 
and errors in axon guidance. Neuron 14(1):43-56 
 78.  Wang JJ, Rabizadeh S, Tasinato A, Sperandio S, Ye X, Green M, Assa-Munt N, 
Spencer D, Bredesen DE. 2000. Dimerization-dependent block of the 
proapoptotic effect of p75(NTR). J. Neurosci. Res. 60(5):587-93 
 79.  Wang KC, Kim JA, Sivasankaran R, Segal R, He Z. 2002. P75 interacts with the 
Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 
420(6911):74-8 
 66 
 
 80.  Wiesmann C, de Vos AM. 2001. Nerve growth factor: structure and function. 
Cell Mol. Life Sci. 58(5-6):748-59 
 81.  Wiesmann C, Ultsch MH, Bass SH, de Vos AM. 1999. Crystal structure of nerve 
growth factor in complex with the ligand-binding domain of the TrkA 
receptor. Nature 401(6749):184-8 
 82.  Xie Y, Tisi MA, Yeo TT, Longo FM. 2000. Nerve growth factor (NGF) loop 4 
dimeric mimetics activate ERK and AKT and promote NGF-like 
neurotrophic effects. J. Biol. Chem. 275(38):29868-74 
 83.  Yuan XB, Jin M, Xu X, Song YQ, Wu CP, Poo MM, Duan S. 2003. Signalling 
and crosstalk of Rho GTPases in mediating axon guidance. Nat. Cell 
Biol. 5(1):38-45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
 
Appendix A 
 
Procedure for cerebellar granule neurons (CGN) 
Procedure: 
Rat pups 3-4 days old. 
1. cut heads of the pups behind the ears. Cut in the midline of the sculp all the way to the nose 
(take care not to damage the brain). Pull the two parts of the skin under the head. Cut carefully 
to the right of the neck and up to just under the hemisphere and across the neck. Lift up the 
loosened part with the forceps and take the cerebellum out and keep it in solution 1 on ice. 
2. Cut off the middle-part of the cerebellum. Place the end pieces on the top of the Petri dish. Chop 
with sterile scalpel blade first one way and thereafter again after turning the Petri dish 90º. 
3. Take 1ml of solution 2 37 ºC (trypsin) add 600µl to a new 10ml tube and the rest to the 
cerebellum. Pippette the cells to the tube. Keep on 37 ºC. Postnatal pups 3-4 days for 8-10min 
and pups at 7-8 days for 14min (10-11). 
4. Add 3ml solution 4 (mild trypsin inhibitor). 
5. Cfg. 1500 rpm 2min. 
6. Discard supernatant. Fill up with 1.5ml solution 3 (trypsin inhibitor) resuspend with the 1ml 
blue tip (20 times) to make resuspension, carefully. 
7. Centrifuge at 100rpm for 30 seconds. Transfer supernatant with pipette to a new tube. 
8. Add 3ml of solution 5 and cfg. 10min at 700rpm. 
9. Resuspend the cells in a suitable volume of medium. Count 14 areas (Burke-Turk). Divide the 
numbers with 14 and multiply by 250.000 = cells per ml. 
Make ready: 
Outside cell room:           Rat 
                                         Plastic bag 
                                         Blue cover 
                                         Dissection equipment 
                                         Ice bath in weighing tray 
                                         Petri dish 
 
In cell room:                     Petri dish 
                                         1 scalpel 
                                         Pipettes + tips 
                                         Counting chamber 
                                         Solutions (prewarm solution 2 at 37 ºC) 
                                         2 x 10ml tubes 
                                         Calculator, paper, pen 
                                         Media 
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Appendix B 
 
Primary cell culture 
 
Krebs buffer: 
NaCl                 7.07g (120.90mM) 
KCl 0.36g (4.83mM) 
KH2PO4 0.166g (1.22mM) 
NaHCO3 2.14g (25.50mM) 
Glucose 2.57g (13.00mM) 
Phenolred 0.015g 
Dissolve in 1L sterile milli-Q water. 
Sterile Krebs buffer is provided from substrate department, Panum. 
 
MgSO4 stock solution, 150mM: 
3.7g MgSO4·7(H2O) in 100ml sterile water. Sterile filter. 
CaCl2 stock solution, 0.11M: 
0.162g CaCl2·2(H2O) in 10 ml sterile water. Sterile filter. 
 
Solutions: Sol 1:                                       (ca. 20ml/tube) 
100 ml Krebs buffer 
0.3g bovine serum albumine 
0.8ml 3.8% MgSO4-stock solution 
2ml 1M HEPES solution to 20mM 
 
Sol 2:                                                         (ca. 1.5ml/tube) 
12.5 ml sol 1 
2.45mg trypsin 
 
Sol 3:                                                         (ca. 1.5ml/tube) 
10ml sol 1 
0.8mg DNAse I 
5.2mg soybean trypsin inhibitor 
100µl 3.8% MgSO4-stock solution 
 
Sol 4:                                                         (ca. 3.5ml/tube) 
10.5ml sol 1 2 ml sol 3 
 
Sol 5:                                                         (ca. 3.5ml/tube) 
12.5ml sol 1 
15µl from 1.2% CaCl2-stock solution 
100µl 3.8% MgSO4 stock solution 
 
Sterile filter 
All solutions into 10ml tubes and store at -20ºC. 
 
 
 
